Nuo Therapeutics (AURX) 10-K 31 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Mar. 20, 2015	Jun. 30, 2014
Document Information [Line Items]
Entity Registrant Name	NUO THERAPEUTICS, INC.
Entity Central Index Key	1091596
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	NUOT
Entity Common Stock, Shares Outstanding		125,680,100
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$39

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$15,946,425	$3,286,713
Short-term investments, restricted	53,391	53,257
Accounts and other receivable, net	1,889,327	3,926,681
Inventory, net	556,620	1,111,507
Prepaid expenses and other current assets	2,338,990	1,258,282
Deferred costs, current portion	1,091,387	316,551
Total current assets	21,876,140	9,952,991
Property and equipment, net	925,171	919,469
Deferred costs	3,547,007	482,349
Intangible assets, net	28,747,770	33,768,954
Goodwill	1,128,517	1,128,517
Total assets	56,224,605	46,252,280
Current liabilities
Accounts payable	1,877,736	3,351,844
Accrued expenses	6,218,224	4,666,828
Deferred revenues, current portion	402,377	740,990
Note payable, current portion	0	1,800,000
Total current liabilities	8,498,337	10,559,662
Notes payable	0	3,620,593
Convertible debt, net of debt discount	325,553	202,658
Deferred revenues	1,039,475	1,441,852
Derivative liabilities	29,846,821	3,248,595
Other liabilities	546,867	366,926
Total liabilities	40,257,053	19,440,286
Commitments and contingencies (See Note 18)
Conditionally redeemable common stock (909,091 issued and outstanding)	500,000	500,000
Stockholders' equity
Common stock; $.0001 par value, authorized 425,000,000 shares; 2014 issued and outstanding - 125,680,100 shares; 2013 issued and outstanding - 107,164,855 shares	12,477	10,626
Common stock issuable	392,950	432,100
Additional paid-in capital	125,173,973	117,097,844
Accumulated deficit	-110,111,848	-91,228,576
Total stockholders' equity	15,467,552	26,311,994
Total liabilities and stockholders' equity	$56,224,605	$46,252,280

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Dec. 31, 2014	Dec. 31, 2013
Temporary equity, shares issued	909,091	909,091
Temporary equity, shares outstanding	909,091	909,091
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized	425,000,000	200,000,000
Common stock, issued	125,680,100	107,164,855
Common stock, outstanding	125,680,100	107,164,855

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenues
Product sales	$5,849,330	$10,498,726
License fees	402,264	167,657
Royalties	1,510,340	703,744
Other revenue	0	201,311
Total revenues	7,761,934	11,571,438
Cost of revenues
Cost of sales	6,594,006	8,363,902
Cost of royalties	176,737	89,290
Total cost of revenues	6,770,743	8,453,192
Gross profit	991,191	3,118,246
Operating expenses
Salaries and wages	8,473,427	7,319,407
Consulting expenses	1,401,381	2,148,983
Professional fees	1,221,462	1,156,868
Research, development, trials and studies	2,623,541	3,798,398
General and administrative expenses	5,978,429	6,789,660
Impairment of trademarks and IPR&D	4,683,829	0
Total operating expenses	24,382,069	21,213,316
Loss from operations	-23,390,878	-18,095,070
Other income (expense)
Interest, net	-3,434,783	-1,680,023
Change in fair value of derivative liabilities	8,100,922	-470,052
Loss on disposal of fixed assets	-131,456	0
Other	-7,493	15,374
Total other income (expenses)	4,527,190	-2,134,701
Loss before provision for income taxes	-18,863,688	-20,229,771
Income tax provision	19,584	18,589
Net loss	($18,883,272)	($20,248,360)
Loss per common share - Basic and diluted	($0.16)	($0.20)
Weighted average shares outstanding - Basic and diluted	120,516,225	103,620,046

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Total	Conditionally Redeemable Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Issuable [Member]	AccumulatedDeficit [Member]
Balance at Dec. 31, 2012	$38,003,911	$0	$9,381	$108,485,646	$489,100	($70,980,216)
Balance (in shares) at Dec. 31, 2012			93,808,386
Amendment to contingent consideration for Aldagen acquisition	1,006,159	0	0	1,006,159	0	0
Warrants issued for credit and security agreement	580,394	0	0	580,394	0	0
Warrants issued for term loan modification	455,275	0	0	455,275	0	0
Common stock issued for release of security interest in patents	325,693	0	25	325,668	0	0
Common stock issued for release of security interest in patents (in shares)			250,000
Common stock issued pursuant to equity purchase agreements executed in February 2013	601,945	0	189	601,756	0	0
Common stock issued pursuant to equity purchase agreements executed in February 2013 (in shares)			1,890,261
Common stock issued upon conversion of 4% Convertible Promissory Note	523,927	0	160	523,767	0	0
Common stock issued upon conversion of 4% Convertible Promissory Note (in shares)			1,600,219
Common stock issued pursuant to private offering completed in First Quarter	4,057,188	500,000	818	4,056,370	0	0
Common stock issued pursuant to private offering completed in First Quarter (in shares)			9,090,911
Common stock issued pursuant to equity purchase agreements executed in October 2010	303,000	0	45	302,955	0	0
Common stock issued pursuant to equity purchase agreements executed in October 2010 (in shares)			450,000
Common stock issued to holder of pre-bankruptcy Series A Preferred stock, pursuant to reorganization plan	0	0	3	39,147	-39,150	0
Common stock issued to holder of pre-bankruptcy Series A Preferred stock, pursuant to reorganization plan (in shares)			27,000
Stock-based compensation related to stock, options and warrants issued for services rendered by--
Employees and Directors	676,185	0	0	676,185	0	0
Other parties	26,678	0	4	44,524	-17,850	0
Other parties (in shares)			37,500
Other changes (in shares)			10,578
Net loss	-20,248,360	0	0	0	0	-20,248,360
Other changes	-1	0	1	-2	0	0
Balance at Dec. 31, 2013	26,311,994	500,000	10,626	117,097,844	432,100	-91,228,576
Balance (in shares) at Dec. 31, 2013			107,164,855
Common stock issued pursuant to equity purchase agreements executed in February 2013	1,754,565	0	379	1,754,186	0	0
Common stock issued pursuant to equity purchase agreements executed in February 2013 (in shares)			3,793,865
Common stock issued upon conversion of 4% Convertible Promissory Note	456,762	0	89	456,673	0	0
Common stock issued upon conversion of 4% Convertible Promissory Note (in shares)			886,690
Common stock issued upon conversion of 10% Convertible Promissory Note	1,375,972	0	598	1,375,374	0	0
Common stock issued upon conversion of 10% Convertible Promissory Note (in shares)			5,981,859
Common stock issued pursuant to private offering completed in First Quarter	1,911,695	0	384	1,911,311	0	0
Common stock issued pursuant to private offering completed in First Quarter (in shares)			3,846,154
Warrants issued in connection with private offering completed in First Quarter 2014	-1,121,235	0	0	-1,121,235	0	0
Expiration of December 2013 Bridge Note warrant provisions in June 2014	1,331,776	0	0	1,331,776	0	0
Common stock issued to holder of pre-bankruptcy Series A Preferred stock, pursuant to reorganization plan	0	0	3	39,147	-39,150	0
Common stock issued to holder of pre-bankruptcy Series A Preferred stock, pursuant to reorganization plan (in shares)			27,000
Common stock issued in connection with the Deerfield Facility	1,050,000	0	271	1,049,729	0	0
Common stock issued in connection with the Deerfield Facility (in shares)			2,709,677
Common stock issued pursuant to the second amendment to the Aldagen Holding LLC exchange and purchase agreement	0	0	127	-127	0	0
Common stock issued pursuant to the second amendment to the Aldagen Holding LLC exchange and purchase agreement (in shares)			1,270,000
Stock-based compensation related to stock, options and warrants issued for services rendered by--
Stock-based compensation related to stock, options and warrants issued for services rendered	1,279,295	0	0	1,279,295	0	0
Net loss	-18,883,272	0	0	0	0	-18,883,272
Balance at Dec. 31, 2014	$15,467,552	$500,000	$12,477	$125,173,973	$392,950	($110,111,848)
Balance (in shares) at Dec. 31, 2014			125,680,100

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($18,883,272)	($20,248,360)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense	31,773	75,165
Loss on reserve for inventory obsolesence	90,000	0
Depreciation and amortization	613,500	1,092,143
Stock-based compensation	1,279,295	717,863
Change in fair value of derivative liabilities	-8,100,922	470,052
Non-cash interest expense:
Amortization of deferred costs	1,112,890	248,606
Amortization of debt discount	589,692	323,146
Deferred income tax provision	19,584	18,589
Loss (Gain) on disposal of assets	131,456	-594,173
Loss on abandonment of lease	242,466	0
Impairment of IPR&D and trademarks	4,683,829	0
Effect of amendment to contingent consideration	0	1,006,159
Loss on extinguishment of debt	0	19,868
Effect of issuance of warrants for term loan modification	0	303,517
Change in operating assets and liabilities, net of those acquired:
Accounts and other receivable, net	2,005,581	-2,268,104
Inventory	464,887	58,590
Prepaid expenses and other current assets	-1,080,842	-210,153
Accounts payable	-1,474,108	1,917,680
Accrued expenses	1,570,877	3,288,621
Deferred revenues	-740,990	2,182,842
Other liabilities	21,034	196,953
Net cash used in operating activities	-17,423,270	-11,400,996
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment acquisitions	-482,962	-750,697
Proceeds from sale of equipment	133,767	2,139,672
Net cash provided by (used in) investing activities	-349,195	1,388,975
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of debt, net	32,967,060	6,240,797
Proceeds from issuance of common stock, net	3,666,260	5,462,132
Repayment of note payable	-6,201,143	-1,020,000
Net cash provided by financing activities	30,432,177	10,682,929
Net increase in cash	12,659,712	670,908
Cash, beginning of period	3,286,713	2,615,805
Cash, end of period	$15,946,425	$3,286,713

Business_and_Presentation

Business and Presentation	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	Note 1 — Business and Presentation
	Description of Business
	At our 2014 Annual Meeting, our shareholders voted to approve the name change amendment to our Certificate of Incorporation. The new name of our Company is “Nuo Therapeutics, Inc.” and the name change was effective upon filing of the Certificate of Amendment to our Certificate of Incorporation in the State of Delaware. Nuo Therapeutics, Inc., formerly Cytomedix, Inc., (“Nuo Therapeutics,” the “Company,” “we,” “us,” or “our”) is a biomedical company marketing products within the U.S. and internationally. We commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The use of autologous from self-biological therapies for tissue repair and regeneration is part of a transformative clinical strategy designed to improve long term recovery in complex chronic conditions with significant unmet medical needs. Growth drivers in the U.S. include Medicare coverage for the treatment of chronic wounds under a National Coverage Determination when registry data is collected under Coverage with Evidence Development (“CED”), and a worldwide distribution and licensing agreement that allows our partner to promote the Angel System for all uses other than wound care.
	Our current commercial offerings consist of point of care technologies for the safe and efficient separation of autologous blood and bone marrow to produce platelet based therapies or cell concentrates. We currently have two distinct platelet rich plasma (“PRP”) devices, the Aurix™  System (formerly known as the AutoloGelTM System) for wound care and the Angel ™ concentrated Platelet Rich Plasma (“cPRP”) System for orthopedics markets. Approximately 73% of our sales are in the United States, where we sell our products through direct sales representatives and distributors. Since August 8, 2013, Arthrex, Inc. (“Arthrex”), as our exclusive distributor for Angel, accounted for 100% of our Angel sales.
	Since our inception, we have financed our operations by raising debt, issuing equity and equity-linked instruments, licensing arrangements, royalties, and product revenues. We have incurred, and continue to incur, recurring losses and negative cash flows. On March 31, 2014, we entered into a $35,000,000 convertible debt facility, $9,000,000 of which was funded on March 31, 2014 and the remaining $26,000,000 was funded on June 25, 2014. In addition, on March 31, 2014 we raised $2.0 million of gross proceeds from the sale of our common stock and warrants to an accredited investor (See Note 11 – Debt and Note 13 - Equity for additional details.) We used approximately $5.9 million of the net proceeds from these transactions to retire outstanding debt and interest, approximately $0.3 million to repay a portion of previously outstanding convertible debt and interest, and we converted approximately $3.1 million previously outstanding convertible debt and interest into common stock (See Note 11 - Debt for additional details.)
	At December 31, 2014, we had approximately $15.9 million of cash on hand. Our operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, lack of operating history and uncertainty of future profitability and possible fluctuations in financial results. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. We believe that our current resources, expected revenue from current products, including additional revenue expected to be generated from our increased marketing efforts, royalty revenue and license fee revenue will be adequate to maintain our operations through at least the end of 2015. Accordingly, management believes the going-concern basis is appropriate for the accompanying consolidated financial statements.
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In our opinion, the accompanying consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. Certain prior period information has been reclassified to conform to the current period presentation.
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned and controlled subsidiary. All significant inter-company accounts and transactions are eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, allowance for doubtful accounts, valuation of derivative liabilities, valuation and probability of contingent liabilities, fair value of long-lived assets, deferred taxes and associated valuation allowance, and the depreciable lives of fixed assets (including intangible assets and goodwill). Actual results could differ from those estimates.
	Cash Equivalents
	We consider all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.
	In connection with the Deerfield Facility Agreement (See Note 7 - Debt for additional details), the Company is required to maintain a compensating cash balance of $5,000,000 in deposit accounts subject to control agreements in favor of the lenders.
	Approximately $15,486,000 and $2,667,000 held in financial institutions was in excess of FDIC insurance at December 31, 2014 and 2013 respectively.
	Accounts Receivable and Credit Concentration
	We generate accounts receivable from the sale of our products. Our trade receivables balance at December 31, 2014 was primarily from Arthrex (64%). In addition, Arthrex accounted for 91% and 47% of total products sales in 2014 and 2013, respectively. No other single customer accounted for more than 5% of total product sales.
	We provide for a reserve against receivables for estimated losses that may result from a customer’s inability or unwillingness to pay. The allowance for doubtful accounts is estimated primarily based upon historical write-off percentages, known problem accounts, and current economic conditions. Accounts are written off against the allowance for doubtful accounts when we determine that amounts are not collectable. Recoveries of previously written-off accounts are recorded when collected. At December 31, 2014 and December 31, 2013, we maintained an allowance for doubtful accounts of $32,000 and $16,000, respectively.
	We use single suppliers for several components of the Angel and Aurix™ product lines. We outsource the manufacturing of various products, including component parts for Angel, to contract manufacturers. While we believe these manufacturers to demonstrate competency, reliability and stability, there is no assurance that one or more of them will not experience an interruption or inability to provide us with the products needed to satisfy customer demand. Additionally, while most of the components of Aurix™ are generally readily available on the open market, a reagent, bovine thrombin, is available exclusively through Pfizer, with whom we have an established vendor relationship.
	During 2014 and 2015, we devoted substantial resources to enhancing and improving the Angel Product Line to meet new and additional regulatory requirements. During the period that we have been implementing the modifications, we were unable to meet our customer’s demand for Angel devices. As a result, our sales were lower than expected and in addition, we incurred a charge to earnings of $600,000 during the year ended December 31, 2014, reflecting our expected costs for refurbishment and design improvements for the units in circulation. Although we believe that we have completed all the necessary design modifications to the Angel Products, we cannot be sure that we will not continue to experience delays and additional costs in the future.
	Inventory
	The Company’s inventory is produced by third party manufacturers and consists primarily of finished goods. Inventory cost is determined on a first-in, first-out basis and is stated at the lower of cost or net realizable value. The Company maintains an inventory of kits, reagents, and other disposables that have shelf lives that generally range from 18 months to five years. We provide for a reserve against inventory for estimated losses that may result in excess and obsolete inventory (i.e. from the expiration of products).
	The Company’s reserve for expired inventory is estimated based upon the inventory’s remaining shelf life and our anticipated ability to sell such inventory, which is estimated utilizing historical usage and future forecasts, within its remaining shelf life. At December 31, 2014 and 2013 the Company maintained a reserve for expired and excess and obsolete inventory of $90,000 and $0, respectively. Expired products are segregated and used for demonstration purposes only; the Company records the associated expense for this reserve to cost of sales on the consolidated statement of operations.
	Property and Equipment
	Property and equipment is stated at cost less accumulated depreciation and is depreciated, using the straight-line method, over its estimated useful life ranging from three to five years for all assets except for furniture, lab, and manufacturing equipment which is depreciated over seven and ten years, respectively. Leasehold improvements are stated at cost less accumulated depreciation and is depreciated, using the straight-line method, over the lesser of the expected lease term or its estimated useful life ranging from three to six years. Amortization of leasehold improvements is included in depreciation expense. Maintenance and repairs are charged to operations as incurred. When assets are disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in other income (expense).
	Centrifuges may be sold, leased, or placed at no charge with customers. Depreciation expense for centrifuges that are available for sale, leased, or placed at no charge with customers are charged to cost of sales. Angel centrifuges are sold directly to our worldwide distributor, Arthrex, and unless used for internal purposes, no longer recorded as property and equipment. When Angel centrifuges were sold to Arthrex for the year ended 2013, the net book value was charged to cost of sales. Depreciation expense for centrifuges used for sales and marketing and other internal purposes are charged to operations.
	Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets.
	Exit Activities
	On May 5, 2014, we announced preliminary efficacy and safety results of our RECOVER-Stroke Phase 2 clinical trial in patients with neurological damage arising from ischemic stroke and treated with ALD-401. Observed improvements in the primary endpoint (mean modified Rankin Score or mRS) of the trial were not clinically or statistically significant. In light of this outcome, we discontinued further funding of the ALD-401 development program, decided to close our facilities in Durham, NC, and terminated certain employees.
	The discontinuance of this development program is considered an exit activity. As such, we recognized the following expenses in the second and third quarters of 2014:
		Quarter ended
		June 30, 2014		September 30, 2014
	Severance costs	$	320,000	$	-
	Loss on abandonment of lease		-		243,000
	Loss on disposal of assets		-		132,000
	Total	$	320,000	$	375,000
	An accrual of approximately  $413,000 for the loss on abandonment of the lease, remained at December 31, 2014. The accrued loss will be amortized over the life of the lease against future rental payments made and sublet income payments received. Severance expense is classified as “salaries and wages” and the loss on abandonment and loss on disposal of assets is classified in “Other income (expense) Loss on disposal of fixed assets” in the accompanying consolidated statements of operations. The accrued loss on abandonment is included in accrued expenses and other liabilities in the accompanying  consolidated balance sheets.
	Intangible Assets and Goodwill
	Intangible assets were acquired as part of our acquisition of the Angel business and Aldagen, and consist of definite-lived and indefinite-lived intangible assets, including goodwill.
	Definite-lived intangible assets
	Our definite-lived intangible assets include trademarks, technology (including patents) and customer relationships, and are amortized over their useful lives and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, we test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), we would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. We periodically reevaluate the useful lives for these intangible assets to determine whether events and circumstances warrant a revision in their remaining useful lives. During the second quarter of 2014, as a result of recent events and changes in circumstances, the Company performed an assessment of our trademarks and concluded that the carrying value of the trademarks was impaired. (See Note 8 — Goodwill and Identifiable Intangible Assets for additional details.)
	Indefinite-lived intangible assets
	We evaluate our indefinite-lived intangible asset, consisting solely of in-process research and development (“IPR&D”) acquired in the Aldagen acquisition, for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and at least on an annual basis on October 1 of each year, by comparing the fair value of the asset with its carrying amount. If the carrying amount of the intangible asset exceeds its fair value, we would recognize an impairment loss in the amount of that excess. During the second quarter of 2014 the Company performed an assessment of our IPR&D as of June 30, 2014, as a result of recent events and changes in circumstances, and concluded that the carrying value of the IPR&D was impaired. Our annual impairment evaluation of indefinite lived intangible assets was performed as of October 1, 2014, and it was determined that there was no additional impairment of the recorded balances. (See Note 8 — Goodwill and Identifiable Intangible Assets for additional details.)
	Goodwill
	Goodwill represents the purchase price of acquisitions in excess of the amounts assigned to acquired tangible or intangible assets and assumed liabilities. Amounts allocated to goodwill are tax deductible in all relevant jurisdictions. As a result of our acquisition of Aldagen in February 2012, we recorded goodwill of approximately $422,000. Prior to the acquisition of Aldagen, we had goodwill of approximately $707,000 as a result of the acquisition of the Angel business in April 2010.
	We conduct an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value impaired. The Company conducted an impairment test of our Goodwill as of June 30, 2014, as a result of recent events and changes in circumstances, and concluded that Goodwill was not impaired. (See Note 5 — Goodwill and Intangible Assets for additional details.) The Company also conducted an impairment test of our Goodwill as of October 1, 2014, and concluded that Goodwill was not impaired.
	Conditionally Redeemable Common Stock
	The Maryland Venture Fund (“MVF,” part of Maryland Department of Business and Economic Development) has an investment in our common stock, and can require us to repurchase the common stock, at MVF’s option, upon certain events outside of our control; provided, however, that in the event that, at the time of either such event our securities are listed on a national securities exchange, the foregoing repurchase will not be triggered. MVF’s common stock are classified as “contingently redeemable common shares” in the accompanying consolidated balance sheets.
	Income Taxes
	The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted.
	For the year ended December 31, 2014, the income tax provision relates exclusively to a deferred tax liability associated with the amortization of goodwill. The Company has analyzed filing positions in all of the federal and state jurisdictions where it is required to file income tax returns, as well as all open tax years in these jurisdictions. All tax years are subject to examination for the Company’s federal return due to our net operating loss carry-forward. The Company believes that its income tax filing positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded.
	The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income before taxes. There were no such items for 2014 and 2013.
	Revenue Recognition
	We recognize revenue when the four basic criteria for recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) consideration is fixed or determinable; and (4) collectability is reasonably assured.
	Sales of products
	We provide for the sale of our products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recognized upon shipment of products to the customers. We do not maintain a reserve for returned products as in the past those returns have not been material and are not expected to be material in the future.
	Usage or leasing of blood separation equipment
	As a result of the acquisition of the Angel ™ business in 2010, we acquired various multiple element revenue arrangements that combine the (i) usage or leasing of blood separation processing equipment, (ii) maintenance of processing equipment, and (iii) purchase of disposable processing sets and supplies. We assigned these multiple element revenue arrangements to Arthrex on August 7, 2013. (See Note 3 — Distribution and License Agreement with Arthrex for additional details.) Under these arrangements, the total arrangement consideration was allocated to the various elements based on their relative estimated selling prices. The usage of the blood separation processing equipment was accounted for as an operating lease; since customer payments were contingent upon the customer ordering new products, rental income was recorded following the contingent rental method when rental income was earned and collectability was reasonably assured. The sale of disposable processing sets and supplies and maintenance were deemed a combined unit of accounting; since (a) any consideration for disposable processing sets and supplies and maintenance was contingent upon the customer ordering additional disposable processing sets and supplies and (b) both the disposable products and maintenance services were provided over the same term, we recognized revenue for this combined unit of accounting following the contingent revenue method at the time disposable products were delivered based on prices contained in the agreement.
	Percentage-based fees on licensee sales of covered products are generally recorded as products are sold by licensees and are reflected as “Royalties” in the consolidated statements of operations. Direct costs associated with product sales and royalty revenues are recorded at the time that revenue is recognized.
	Deferred revenue at December 31, 2014 consists of prepaid licensing revenue of approximately $1,442,000. Revenue of approximately $402,000 related to the prepaid license was recognized during the year ended December 31, 2014. On January 1, 2013 a medical device excise tax came into effect that required manufacturers to pay tax of 2.3% on the sale of certain medical devices. We report the medical device excise tax on a gross basis, recognizing the tax as both revenue and cost of sales.
	Segments and Geographic Information
	We operate in one business segment. Approximately 27% and 9% of our product sales were generated outside of the United States for the years ended December 31, 2014 and 2013, respectively.
	Research and Development Expenses
Research and development costs are expensed as incurred and primarily consist of expenses relating to product development. Research and development costs do not include salaries and wages, which are included in “Salaries and Wages” in the Consolidated Statements of Operations, and the allocation of overhead and other indirect costs, which are included in the “Consulting expenses” and “General and Administrative expenses” lines in the Consolidated Statements of Operations.
Stock-Based Compensation
The Company, from time to time, may issue stock options or stock awards to employees, directors, consultants, and other service providers under its 2002 Long-Term Incentive Plan (“LTIP”) or 2013 Equity Incentive Plan (“EIP”). In some cases, it has issued compensatory warrants to service providers outside the LTIP or EIP (See Note 13 – Equity for additional details).
All equity-based compensation is estimated on the issuance date of grant using the Black-Scholes-Merton option-pricing formula. The assumptions used in the model for the LTIP and EIP are summarized in the following table:
	2014		2013
Risk free rate	0.1-1.7	%	0.4-1.4	%
Weighted average expected years until exercise	6.3		5.9
Expected stock volatility	118-127	%	96-135	%
Dividend yield	—		—
For stock options, expected volatilities are based on historical volatility of the Company’s stock. Company data was utilized to estimate option exercises and employee terminations within the valuation model for the year ended December 31, 2014 and peer company data to estimate option exercises and employee terminations within the valuation model for the year ended December 31, 2013. Expected years until exercise represents the period of time that options are expected to be outstanding. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The Company estimated that the dividend rate on its Common stock will be zero.
The fair value of stock options or compensatory warrants issued to service providers utilizes the same methodology with the exception of the expected term. For these awards to non-employees, the Company estimates that the options or warrants will be held for the full term.
Stock-based compensation for awards granted to non-employees is periodically remeasured as the underlying options and warrants vest. The Company recognizes an expense for such awards throughout the performance period as the services are provided by the non-employees, based on the fair value of these options and warrants at each reporting period.
The Company estimates the fair value of stock awards based on the closing market value of the Company’s stock on the date of grant.
Basic and Diluted Earnings (Loss) per Share
Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding during the period.
For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.
For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The total number of anti-dilutive shares, common stock options, warrants exercisable for common stock, convertible preferred stock and convertible debt, which have been excluded from the computation of diluted earnings (loss) per share, were 200,989,054 and 61,134,957 for the years ended December 31, 2014 and 2013, respectively.
Defined Contribution Plans
The Company sponsors a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time U.S. employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. Participants are always fully vested in their contributions. The Company makes employer matching contributions, which also vest immediately. This plan is designated as a “Safe Harbor” plan. During 2014 and 2013, the Company contributed approximately $175,000 and $164,000 in cash to the plan.
Recent Accounting Pronouncements
ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” The Financial Accounting Standards Board (FASB or Board) and the International Accounting Standards Board (IASB) (collectively, the Boards) jointly issued a long-awaited standard that will supersede virtually all of the revenue recognition guidance in U.S. GAAP. The FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606). The FASB has set an effective date of fiscal years beginning after December 15, 2016. Early adoption is not permitted for public entities. FASB ASU No. 2014-09 will amend FASB Accounting Standards Codification™ (ASC) by creating Topic 606, Revenue from Contracts with Customers and Subtopic 340-40, Other Assets and Deferred Costs—Contracts with Customers. This document reorganizes the guidance contained in FASB ASC 606 (revenue recognition standard), to follow the five step revenue recognition model along with other guidance impacted by this standard. The potential effects of the adoption of ASU 2014-09, Topic 606 on our results of operations and the Company’s consolidated financial statements have not been determined at this time.
ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40) - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Previously, there was no guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. FASB issued ASU 2014-15 to provide guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact, if any, that the adoption will have on its consolidated financial statements.
ASU No. 2014-16, “Derivatives and Hedging (Topic 815) – Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity.” There are predominantly two methods used in current practice by issuers and investors in evaluating whether the nature of the host contract within a hybrid financial instrument issued in the form of a share is more akin to debt or to equity. Additionally, there is diversity in practice with respect to the consideration of redemption features in relation to other features when determining whether the nature of a host contract is more akin to debt or to equity. The objective of this update is to eliminate the use of different methods in practice and thereby reduce existing diversity under GAAP in the accounting for hybrid financial instruments issued in the form of a share. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption, including adoption in an interim period, is permitted. If an entity early adopts the amendments in an interim period, any adjustments shall be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact, if any, that the adoption will have on its consolidated financial statements.

Arthrex_Distributor_and_Licens

Arthrex Distributor and License Agreement	12 Months Ended
	Dec. 31, 2014
Distributors And License Agreement [Abstract]
Arthrex Distributor and License Agreement [Text Block]	Note 2 — Arthrex Distributor and License Agreement
	Arthrex Distributor and License Agreement
	On August 7, 2013, the Company entered into a Distributor and License Agreement (the “Arthrex Agreement”) with Arthrex, Inc., a privately held Florida based company (“Arthrex”). Under the terms of the Arthrex Agreement, Arthrex obtained the exclusive rights to sell, distribute, and service the Company’s Angel Concentrated Platelet System and ActivAt (“Products”), throughout the world, for all uses other than chronic wound care. The Company granted Arthrex a limited license to use the Company’s intellectual property as part of enabling Arthrex to sell the Products. Arthrex will purchase Products from the Company to distribute and service at certain purchase prices, which may be changed after an initial period. Arthrex has the right, on written notice to the Company, to assume responsibility for the manufacture and supply of the Products, either by assuming the Company’s existing manufacturing and supply agreements or by entering into new manufacturing and supply agreements. Arthrex will also pay a certain royalty rate based upon volume of the Products sold. The exclusive nature of Arthrex rights to sell, distribute and service the Products is subject certain existing supply and distribution agreements such that Arthrex may instruct the Company to terminate or not renew any of such agreements. In addition, Arthrex’s rights to sell, distribute and service the Products is not exclusive in the non-surgical dermal and non-surgical aesthetics markets. In connection with execution of the Arthrex Agreement, Arthrex paid the Company a nonrefundable upfront payment of $5 million. The term of the Arthrex Agreement is five years, automatically renewable for an additional three-year period unless Arthrex gives the Company a termination notice at least one year in advance of the end of the initial five-year period. The Arthrex Agreement contains other terms and provisions that are customary to the agreements of this nature. The foregoing description of the Arthrex Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Arthrex Agreement.
	Immediately following the execution of the Arthrex Agreement, the Company, at the request of Arthrex, agreed to temporarily provide certain services to Arthrex during a transition period (“Transition Services”). These Transition Services primarily involved customer service, sales order fulfillment, customer billing and collections, and technical support for the Products. For these services, Arthrex paid the Company an agreed upon fee. The Transition Services period was concluded in the fourth quarter of 2013.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 3 — Fair Value Measurements
	Our balance sheets include various financial instruments that are carried at fair value. Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:
	⋅	Level 1, defined as observable inputs such as quoted prices in active markets for identical assets;
	⋅	Level 2, defined as observable inputs other than Level I prices such as quoted prices for similar assets; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
	⋅	Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
	An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.
	Financial Instruments Carried at Cost
	Short-term financial instruments in our consolidated balance, including accounts receivable, accounts payable and accrued expenses, are carried at cost which approximates fair value, due to their short-term nature. The face value of our long-term convertible debt approximates its fair value.
	Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
	We have segregated our financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. The inputs used in measuring the fair value of cash and short-term investments are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of our funds.
	We account for our derivative financial instruments, consisting solely of certain stock purchase warrants that contain non-standard anti-dilutions provisions and/or cash settlement features, and certain conversion options embedded in our convertible instruments, at fair value using level 3 inputs. We determine the fair value of these derivative liabilities using the Black-Scholes option pricing model when appropriate, and in certain circumstances using binomial lattice models or other accepted valuation practices.
	When determining the fair value of our financial assets and liabilities using the Black-Scholes option pricing model, we are required to use various estimates and unobservable inputs, including, among other things, contractual terms of the instruments, expected volatility of our stock price, expected dividends, and the risk-free interest rate. Changes in any of the assumptions related to the unobservable inputs identified above may change the fair value of the instrument. Increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value.
	When determining the fair value of our financial assets and liabilities using binomial lattice models or other accepted valuation practices, we also are required to use various estimates and unobservable inputs, including in addition to those listed above, the probability of certain events.
	The following table represents the fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis for the year ended December 31, 2014 and 2013:
			As of December 31, 2014
	Description		Level 1		Level 2		Level 3		Total
	Assets
	Investment in money market funds		$	15,736,350	$	-	$	-	$	15,736,350
	Total investment in money market funds		$	15,736,350	$	-	$	-	$	15,736,350
	Liabilities
	Embedded conversion options		$	-	$	-	$	4,362,225	$	4,362,225
	Stock purchase warrants			-		-		25,484,596		25,484,596
	Total derivative liabilities		$	-	$	-	$	29,846,821	$	29,846,821
			As of December 31, 2013
			Level 1		Level 2		Level 3		Total
	Assets
	Investment in money market funds		$	2,303,556	$	-	$	-	$	2,303,556
	Total investment in money market funds		$	2,303,556	$	-	$	-	$	2,303,556
	Liabilities
	Embedded conversion options		$	-	$	-	$	1,515,540	$	1,515,540
	Stock purchase warrants			-		-		1,733,055		1,733,055
	Total derivative liabilities		$	-	$	-	$	3,248,595	$	3,248,595
	The Level 1 assets measured at fair value in the above table are classified as “cash and cash equivalents” in the accompanying consolidated balance sheets.
	The Level 3 liabilities measured at fair value in the above table are classified as “derivative liabilities” in the accompanying consolidated balance sheets. All other gains and losses in the fair value of derivative instruments are classified as the “change in the fair value of derivative instruments” in the accompanying consolidated statements of operations.
	During the years ended December 31, 2014 and 2013, we did not have any transfers between Level 1, Level 2, or Level 3 assets or liabilities.
	The following tables set forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the year ended December 31, 2014 and 2013:
			Balance at				Modification		Effect of						Balance at
			January 1,		Established in		of Convertible		Conversion to		Change in		Reclass to		December 31,
	Description		2014		2014		Debt Agreement		Common Stock		Fair Value		Equity (1)		2014
	Derivative liabilities:
	Embedded conversion options		$	1,515,540	$	8,825,935	$	-	$	-1,932,693	$	-4,046,557	$	-	$	4,362,225
	Stock purchase warrants			1,733,055		29,137,682		-		-		-4,054,365		-1,331,776		25,484,596
			Balance at				Modification								Balance at
			January 1,		Established in		of Convertible		Conversion to		Change in		Reclass to		December 31,
	Description		2013		2013		Debt Agreement		Common Stock		Fair Value		Equity		2013
	Derivative liabilities:
	Embedded conversion options		$	780,960	$	965,484	$	250,361	$	-393,948	$	90,839	$	-178,156	$	1,515,540
	Stock purchase warrants			-		1,353,842		-		-		379,213		-		1,733,055
	(1) Various warrants were reclassified to additional paid-in capital as a result of the expiration of non-standard anti-dilution clauses contained within the warrants.
	In February 2014, we purchased a Certificate of Deposit (“CD”) from a commercial bank in the amount of $53,000. The CD bears interest at an annual rate of 0.10% and matures on June 24, 2015. The $53,000 carrying value of the CD approximates its fair value. This CD collateralizes a letter of credit. (See Note 17 – Commitments and Contingencies for additional details.)
	We have no financial assets and liabilities measured at fair value on a nonrecurring basis.
	Non-Financial Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
	Property and equipment, intangible assets and goodwill are measured at fair value on a non-recurring basis (upon impairment). The intangible assets in the table below are measured at fair value on a non-recurring basis and are presented at fair value as of the date of impairment.
	(See Note 8 — Goodwill and Identifiable Intangible Assets for additional details.)
	We determined the fair value for IPR&D by using the royalty savings method of the income approach. In applying this method, we used the existing royalty income that was being generated by the Company and expected future royalty revenues to get to the expected net cash flows. We then applied an asset-specific discount rate to the forecasted net cash flows to arrive at a net present value amount. Significant estimates and assumptions used in this approach were the (i) amount and timing of the projected revenues; (ii) royalty rate based on comparable IPR&D; (iii) discount rate, which reflects the various risks involved in future cash flows; and (iv) tax rate.
	We determined the fair value for the Trademark by using the royalty savings method of the income approach. In applying this method, we used the expected future royalty revenues, generated by the Trademark, to get to the expected net cash flows. We then applied an asset-specific discount rate to the forecasted net cash flows to arrive at a net present value amount. Significant estimates and assumptions used in this approach were the (i) amount and timing of the projected revenues; (ii) royalty rate based on comparable trademarks; (iii) estimated useful life; and (iv) discount rate, which reflects the various risks involved in future cash flows; and (v) tax rate.
	The following table represents the fair value hierarchy for our non-financial assets that were measured during 2014 (we did not remeasure any of our non-financial assets during 2013):
			Level 1		Level 2		Level 3		Total
	Intangible assets
	Intangible assets - IPR&D		$	—	$	—	$	25,926,000	$	25,926,000
	Intangible assets - Trademarks			—		—		706,229		706,229
	Total		$	—	$	—	$	26,632,229	$	26,632,229
	The carrying fair value of our Aldagen related trademarks and in-process research and development reflect a reduction in their value of approximately $1,025,000 and $3,659,000, respectively, as a result of an impairment loss recognized during the year ended December 31, 2014. These assets are included in “intangible assets, net” in the accompanying consolidated balance sheets. The reduction in value, as of the valuation date is reflected as “Impairment of IPR&D and trademarks” in the accompanying consolidated statements of operations. These assets are not measured at fair value on a recurring basis.
	We have no non-financial assets and liabilities measured at fair value on a recurring basis.

Receivables

Receivables	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Note 4 — Receivables
	Accounts and royalties receivable, net consisted of the following:
		December 31,		December 31,
		2014		2013
	Trade receivables	$	609,179	$	2,449,199
	Other receivables		1,312,617		1,493,979
			1,921,796		3,943,178
	Less allowance for doubtful accounts		-32,469		-16,497
		$	1,889,327	$	3,926,681
	Other receivables consist primarily of royalties and transition service fees due from Arthrex and the cost of raw materials needed to manufacture the Angel products that are sourced by the Company and immediately resold, at cost, to the contract manufacturer.
	The following table reflects the approximate change in allowance for doubtful accounts.
		Balance at		Charged to				Balance at
		Beginning of		Costs and		Balances		End of
		Period		Expenses		charged-off		Period
	Year Ended December 31, 2014
	Allowance for doubtful accounts	$	16,497	$	31,773	$	-15,801	$	32,469
	Year Ended December 31, 2013
	Allowance for doubtful accounts	$	42,709	$	75,166	$	-101,378	$	16,497

Inventory

Inventory	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 5 — Inventory
	Inventory, net consisted of the following:
		December 31,		December 31,
		2014		2013
	Raw materials	$	121,631	$	125,583
	Finished goods		524,989		985,924
			646,620		1,111,507
	Less provision for inventory obsolescence		-90,000		—
		$	556,620	$	1,111,507

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2014
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses And Other Current Assets [Text Block]	Note 6 — Prepaid Expenses and Other Current Assets
	Prepaid expenses and other current assets consisted of the following:
		December 31,		December 31,
		2014		2013
	Prepaid insurance	$	125,106	$	63,096
	Prepaid fees and rent		249,046		151,454
	Deposits and advances		1,360,672	$	279,870
	Prepaid royalties		604,166		724,999
	Other Current Assets		—		38,863
		$	2,338,990	$	1,258,282
	Prepaid fees and rent consist primarily of prepaid service contracts. Deposits and advances consist primarily of payments to the Company’s raw materials suppliers and Angel® centrifuge manufacturers. Other Current Assets was exclusively made up of parts used to refurbish the Angel® centrifuges. Prepaid royalties consist of a cash payment, and the fair value of the common stock and warrant issued for the release of the Worden security interest in patents (See Note 13 - Equity for additional details). The royalty is amortized to cost of sales over the life of the patent. For the years ended December 31, 2014 and 2013, royalty amortization expense was approximately $120,833 and $100,694, respectively.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property Plant And Equipments Disclosure [Text Block]	Note 7 — Property and Equipment
	Property and equipment, net consisted of the following:
		December 31,		December 31,
		2014		2013
	Medical equipment	$	801,463	$	1,278,681
	Office equipment		150,411		86,001
	Software		307,844		—
	Manufacturing equipment		307,851		307,971
	Leasehold improvements		32,130		390,911
			1,599,699		2,063,564
	Less accumulated depreciation and amortization		-674,528		-1,144,095
		$	925,171	$	919,469
	As a result of the Arthrex Agreement (See Note 2 — Arthrex Distributor and License Agreement for additional details.), Angel centrifuges were classified to “Inventory” in the accompanying consolidated balance sheets, whereas they were previously classified as “Property and equipment”.
	For the year ended December 31, 2014 depreciation expense and amortization was approximately $276,000, of which $72,000 was reported as research, development, trials and studies, and $105,000 was reported as cost of sales.
	For the year ended December 31, 2013 depreciation expense and amortization was approximately $726,000, of which $299,000 was reported as research, development, trials and studies, and $310,000 was reported as cost of sales.
	The net book value of property and equipment disposed of was approximately $265,000 in 2014 and $1,543,000 in 2013 (which includes approximately $1,295,000 of existing placed Angel centrifuges sold under the Arthrex Agreement). The disposal of property and equipment was primarily due to the sale of centrifuges and the close-out of our research and development facility.

Goodwill_and_Identifiable_Inta

Goodwill and Identifiable Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	Note 8 — Goodwill and Identifiable Intangible Assets
	Our intangible assets consist of trademarks, technology (including patents), customer relationships, and the IPR&D. These assets are a result of the Angel Business and Aldagen acquisitions. The carrying value of our intangible assets, and the associated amortization, were as follows:
		December 31,		December 31,
		2014		2013
	Trademarks	$	1,047,000	$	2,310,000
	Technology		2,355,000		2,355,000
	Customer relationships		708,000		708,000
	In-process research and development		25,926,000		29,585,000
	Total	$	30,036,000	$	34,958,000
	Less accumulated amortization		-1,288,230		-1,189,046
		$	28,747,770	$	33,768,954
	As a result of our discontinuance of ALD-401 in the second quarter of 2014, we performed an assessment of our Aldagen related trademarks and IPR&D as of June 30, 2014 and determined these assets were impaired. There was no additional impairment recognized since then. At December 31, 2014 the carrying value reflects the impairment charge made to these assets.
	The Company performed a quantitative assessment of our Aldagen related trademarks, and assessed changes to driving factors used in valuing that intangible asset, including the projected revenue stream, discount factor, and remaining useful life, and considered the impact of such changes to the discounted future cash flows used to value the trademarks.  We concluded that the initial fair value of the Aldagen related trademarks of approximately $1.8 million was impaired as of June 30, 2014. An impairment charge of approximately $1.0 million was taken in the three month period ending June 30, 2014 to reflect the current fair value of approximately $0.8 million.
	The Company also performed a quantitative assessment of our IPR&D, and assessed changes to driving factors used in valuing that intangible asset, including the projected diagnostic revenue and expenses as well as the discount factor, and considered the impact of such changes to the discounted future cash flows used to value the IPR&D. We concluded that the initial fair value of the IPR&D of approximately $29.6 million was impaired as of June 30, 2014. An impairment charge of approximately $3.7 million was taken in the three month period ending June 30, 2014 to reflect the current fair value of approximately $25.9 million. Our annual impairment evaluations of indefinite lived intangible assets was performed as of October 1, 2014, and it was determined that there was no additional impairment of the recorded balances. (See Note 3 — Fair Value Measurements for additional details.)
	We are currently conducting (i) a Phase 1/2 clinical trial in critical limb ischemia (PACE) that is being funded by the National Institutes of Health, and (ii) a Phase 1 clinical trial in grade IV malignant glioma following surgery that is funded by Duke University, both using the intellectual property and know-how encompassed by the IPR&D and trademarks. We have no current plans to change our approach with respect to these programs.
	Amortization expense associated with our definite-lived intangible assets of $157,000 was recorded to cost of royalties and approximately $180,000 was recorded to general and administrative expense for the year ended December 31, 2014. Annual amortization expense based on our existing intangible assets and their estimated useful lives is expected to be approximately:
	2015	308,400
	2016	308,400
	2017	308,400
	2018	242,000
	2019	219,900
	Thereafter	1,434,800
	As a result of our discontinuance of ALD-401 in the second quarter of 2014, the Company performed an impairment test of goodwill as of June 30, 2014. We also performed an impairment test of goodwill as of October 1, 2014. We perform a two-step process for measuring for impairment of goodwill. Step 1 of the impairment process is to determine if the fair value of the reporting unit exceeds its carrying value. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, thus the second step of the impairment test is unnecessary. The Company’s goodwill is contained in its sole operating segment and reporting unit. Based on our assessment on June 30, 2014 and October 1, 2014, the fair value of the reporting unit, determined with reference to its quoted market cap, exceeded its carrying value at each date of assessment and the Company determined goodwill was not impaired. Accordingly, the Step Two analysis was not performed.

Accrued_expenses

Accrued expenses	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Accrued Liabilities [Text Block]	Note 9 — Accrued expenses
	Accrued expenses consisted of the following:
		December 31,		December 31,
		2014		2013
	Customer deposits		2,516,202		1,795,803
	Accrued compensation and benefits		984,227		795,584
	Other payables		379,019		242,993
	Accrued interest		1,025,623		2,250
	Due to Arthrex		324,531		1,630,564
	Accrued professional fees		285,446		199,634
	Accrued loss on abandonment of lease, current portion		103,176		—
	Accrued Angel machine refurbishment costs		600,000		—
		$	6,218,224	$	4,666,828
	The amount due to Arthrex consists of payments collected on Angel sales made by Nuo Therapeutics, on behalf of Arthrex, during the transition services period (See Note 2 – Arthrex Distributor and License agreement for additional details.).
	Accrued interest primarily consists of the interest accrued related to the Deerfield convertible debt (See Note 11 – Debt for additional details.).
	We expect to incur machine refurbishment and design improvement costs to refurbish customer placed centrifuges, therefore, an accrual of $600,000 was established for these expected costs and is reflected in “cost of sales” on the statement of operations.

Deferred_Revenue

Deferred Revenue	12 Months Ended
	Dec. 31, 2014
Deferred Revenue [Abstract]
Deferred Revenue Disclosure [Text Block]	Note 10 — Deferred Revenue
	Deferred revenue consists of prepaid licensing revenue from the Arthrex Agreement. Revenue related to prepaid licensing is recognized on a straight-line basis over 5 years, the term of the Arthrex Agreement. Revenue of $402,264 and $167,657 related to the prepaid license was recognized in the years ended December 31, 2014 and 2013, respectively. (See Note 2 — Arthrex Distributor and License Agreement for additional details.)

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 11 — Debt
	Outstanding Debt as of December 31, 2014
	At December 31, 2014 we have outstanding debt consisting of the Deerfield 5.75% convertible debt due March 31, 2019.
	On March 31, 2014, we executed agreements with Deerfield for the issuance of a five-year senior secured convertible credit facility. Under the terms of this agreement, Deerfield agreed to provide to us a convertible credit facility (the “Facility Agreement”) in an amount up to $35 million which was disbursed as follows: (i) the initial draw of $9 million of the Facility Agreement was disbursed on March 31, 2014 (the “First Draw”), and (ii) following the authorization by our shareholders to increase our authorized capital stock (the “Share Authorization Event”), which occurred on June 9, 2014, we were required to draw and Deerfield was required to fund, the remaining $26 million of the Facility Agreement (the “Second Draw”). In addition to the convertible notes, we issued stock purchase warrants to purchase up to 97,614,999 shares of our common stock at an initial exercise price of $0.52 per share (subject to adjustments). (See Note 13 — Equity for additional details.)
	Outstanding amounts under the Facility Agreement are due in full on March 31, 2019. The Facility Agreement is structured as a purchase of senior secured convertible notes (the “Notes”), which bear interest at a rate of 5.75% per annum, payable quarterly in arrears in cash or, at our election after the Second Draw, registered shares of common stock; provided, that during the first five quarters following the closing which was March 31, 2014, we have the option of having all or any portion of accrued interest added to the principal balance of the Facility Agreement. We elected to have all portions of accrued interest added to the principal balance until September 30, 2015 beginning with the interest due for third quarter of 2014.
	Following the Share Authorization Event, which occurred on June 9, 2014, Deerfield has the right to convert the principal amount of the Facility Agreement into shares of our common stock (“Conversion Shares”) at a per share price equal to $0.52. In addition, we granted to Deerfield the option to require the Company to redeem up to 33.33% of the total amount drawn under the Facility Agreement together with any accrued and unpaid interest thereon, on each of the second, third, and fourth anniversaries of the closing with the option right triggered upon the Company’s net revenues failing to be equal or exceed the quarterly milestone amounts set forth in the Facility Agreement. We also granted Deerfield the option to require us to apply 35% of the proceeds received by us in equity-raising transaction(s) to redeem outstanding principal and interest of the Notes, provided that the first $10 million so raised by us will be exempt from this put option. We entered into a security agreement which provides, among other things, that our obligations under the Notes will be secured by a first priority security interest, subject to customary permitted liens, on all our assets. We also entered into a Registration Rights Agreement dated as of the same date (the “Deerfield Registration Rights Agreement”) pursuant to which we agreed to file a registration statement to register the resale of the Conversion Shares and the Deerfield Warrant Shares of our common stock following the Share Authorization Event. Such Registration Rights Agreement was filed on July 10, 2014. (See Note 17 – Commitments and Contingencies for additional details regarding registration rights.)
	As a result of certain non-standard anti-dilution provisions and cash settlement features, we classified the detachable stock purchase warrants and the conversion option embedded in the convertible notes associated with the First Draw and Second Draw as derivative liabilities. The derivative liabilities associated with the First Draw were recorded initially at their estimated relative fair value of approximately $6.6 million and $3.0 million, respectively and those associated with the Second Draw, initially at their estimated relative fair value of approximately $21.5 million and $5.3 million respectively. As a result, we recognized a discount on the convertible notes of $9.0 million associated with the First Draw and $25.8 million associated with the Second Draw. We are amortizing the discount on both of the notes over the term of the notes using the effective interest method. In addition, we re-measure the warrants and the conversion option to fair value at each balance sheet date. The issuance costs, in the form of warrants and fees, related to the First Draw and Second Draw were valued at approximately $1.5 million and $2.6 million, respectively, were recorded as deferred debt issuance costs, and are being amortized to interest expense on a straight-line basis through the maturity date (we determined that the straight-line method of amortization did not yield a materially different amortization schedule from the effective interest method). The issuance costs associated with the Second Draw included a yield enhancement fee, for which we issued 2,709,677 shares of the Company’s commons stock, with a fixed value of approximately $1.1 million which was also recorded as deferred debt issuance costs, and are being amortized to interest expense on a straight-line basis through the maturity date (we determined that the straight-line method of amortization did not yield a materially different amortization schedule from the effective interest method).
	2013 Debt No Longer Outstanding at December 31, 2014
	JP Nevada Trust 12% Note
	On April 28, 2011, we borrowed $2.1 million pursuant to a secured promissory note that matures May 20, 2016. The note accrued interest at a rate of 12% per annum, and required interest-only payments each quarter commencing September 30, 2011, with the then outstanding principal due on the maturity date. The note was secured by our Angel assets. In connection with the issuance of the secured promissory note, we issued the lender a warrant to purchase up to 1,000,000 shares at an exercise price of $0.50 per share, with variable vesting provisions.
	Of the $2,100,000 due under the note, our payment obligations with respect to $1,400,000 under the note were guaranteed by certain insiders, affiliates, and shareholders. In connection with this guarantee, we issued the guarantors warrants to purchase an aggregate of up to 1,500,000 shares, on a pro rata basis based on the amount of the guarantee, at an exercise price of $0.50 per share with variable vesting provisions.
	The warrants issued to the lender and the guarantors were valued at approximately $546,000, were recorded as deferred debt issuance costs, and were being amortized to interest expense on a straight-line basis over the guarantee period (we determined that the straight-line method of amortization did not yield a materially different amortization schedule from the effective interest method).
	On March 31, 2014 in connection with the Deerfield Facility, JP Nevada Trust agreed to subordinate its security interest in the note. In consideration, we issued to the holder a 5-year warrant to purchase 750,000 shares of our common stock at an exercise price of $0.52 per share. The warrants were valued at approximately $14,000 and are classified as derivative liabilities.
	The $2.1 million note with JP Nevada Trust was retired in conjunction with the Second Draw under the Facility Agreement in June 2014 and the warrants expired pursuant to their terms upon repayment of the debt. The corresponding deferred debt issuance costs of $298,000 were charged to interest expense in the consolidated statements of operations and we re-measured the corresponding warrants to fair value at June 30, 2014. (See Note 13 – Equity for additional details.)
	JMJ 4% Convertible Notes
	On July 15, 2011, we issued $1.3 million of our 4% Convertible Notes (the “July 4% Convertible Notes”) to JMJ Financial. The July 4% Convertible Notes were scheduled to mature on May 23, 2016 and included a one-time interest charge of 4% due on maturity. The July 4% Convertible Notes (plus accrued interest) converted at the option of the holder, in whole or in part and from time to time, into shares of our common stock at a conversion rate equal to (i) the lesser of $0.80 per share or (ii) 80% of the average of the three lowest closing prices of our common stock for the previous 20 trading days prior to conversion (subject to a “floor” price of $0.25 per share). On April 28, 2014, the remaining balance of the face amount of the July 4% Convertible Notes and accrued interest were converted into approximately 347,000 shares of common stock at a conversion price of $0.41 per share.
	Mid-Cap Financial Term Loan
	On February 19, 2013, we entered into a Credit and Security Agreement (the “Credit Agreement”) with Mid-Cap Financial (“MidCap”) that provided for aggregate term loan commitments of $7.5 million, subsequently modified to $4.5 million. We received the first tranche of $4.5 million on February 27, 2013. On March 31, 2014, we repaid the term loan in its entirety along with approximately $330,000 in early payment penalties and fees. The balance of the unamortized debt discount of approximately $381,000 and deferred fees of approximately $142,000 were charged to interest expense in the consolidated statements of operations.
	In connection with term loan, we issued the lender a seven-year warrant to purchase 1,079,137 shares of the Company’s Common stock at the warrant exercise price of $0.70 per share. The exercise price and the number of shares issuable upon exercise of the warrant is subject to standard anti-dilution adjustments and contains a cashless exercise provision. The warrants issued to the lender were valued at approximately $568,000, were recorded as a debt discount, and were being amortized to interest expense over the term of the loan (we determined that the straight-line method of amortization did not yield a materially different amortization schedule from the effective interest method). The warrants are classified in equity.
	On December 10, 2013, we revised the exercise price of the warrants to $0.46 per share (“Amendment to the MidCap Warrant”). As a result of the Amendment to the MidCap Warrant, the fair value of the warrants were modified and the change was recognized as an increase to debt discount and amortized over the remaining life of the loan. The change in the fair value of the warrants was approximately $12,000.
	December 2013 Convertible Bridge Note
	On November 21, 2013, we executed agreements with certain investors for the subsequent issuance of 10% subordinated convertible notes (“10% Subordinated Convertible Notes”) and stock purchase warrants, for gross proceeds of up to $3 million. The eventual closing was contingent upon several factors; we received $2.25 million of the expected gross proceeds at the first closing, which occurred on December 10, 2013 after the Company received an acceptable Centers for Medicare and Medicaid Services (“CMS”) reimbursement determination for Aurix™. We received $0.75 million of the gross proceeds in February 2014.
	On March 31, 2014 the holders of the December 2013 convertible bridge notes (except for one holder), agreed to convert their outstanding notes pursuant to its terms, converting into 5,981,859 shares of common stock. The Company repaid, in its entirety, the portion of the debt excluded from the conversion (including interest and prepayment penalties) pursuant to its terms, for a total cash payment of approximately $339,000. The unamortized balance of the related debt discount, deferred fees, and derivative liability for the embedded conversion feature, were reclassified to additional paid-in capital.
	The conversion option embedded in the 10% Subordinated Convertible Notes and related warrants issued to the investors was accounted for as a derivative liability and was recorded at full fair value relative to the total gross proceeds which totaled $2.25 million at December 10, 2013, resulting in a debt discount of $2.25 million. The debt discount was amortized as additional interest expense using the interest rate method through the maturity date. The embedded conversion option and the warrants were recorded at fair value and marked to market at each period, with the resulting change in fair value reflected as “change in fair value of derivative liabilities” in the accompanying consolidated statements of operations.
	In connection with the issuance of the Notes, we also agreed to issue to the investors in the Offering five-year warrants (the “Warrants”) to purchase shares of our Common stock in the amount equal to 75% of the number of shares into which the Notes may be converted at the Closing, at an exercise price equal to 125% of the Market Price (as defined). The Warrants also contain non-standard anti-dilution adjustments and contain certain net settlement features.
	Warrants issued to the placement agent were valued at approximately $69,000, were recorded as deferred debt issuance costs, and were being amortized to interest expense on a straight-line basis through the maturity date (we determined that the straight-line method of amortization did not yield a materially different amortization schedule from the effective interest method).
	As a result of the scheduled expiration of non-standard anti-dilution clauses contained within the investors and placement agent warrants, the warrants were reclassified to equity at their fair value on June 9, 2014.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 12 — Income Taxes
	Income tax (expense) benefit for the years ended December 31, 2014 and 2013 consisted of the following:
		2014			2013
	Current:
	Federal	$	—		$	—
	State		—			—
	Deferred:
	Federal		9,513,282			-212,022
	State		952,533			-401,215
	Net operating loss carryforward		7,764,117			4,243,885
	Valuation Allowance		-18,249,516			-3,649,237
	Total income tax (expense) benefit	$	-19,584		$	-18,589
	Significant components of Nuo Therapeutics’ deferred tax assets and liabilities consisted of the following at December 31:
		2014			2013
	Deferred tax assets:
	Stock-based compensation	$	5,942,000		$	5,371,000
	Tax credits		3,162,000			2,895,000
	Deferred revenue		575,000			861,000
	Start-up and organizational costs		276,000			272,000
	Tax deductible Goodwill		88,000			112,000
	Property and equipment		56,000			240,000
	Other		389,000			153,000
	Total deferred tax assets		10,488,000			9,904,000
	Deferred tax liabilities:
	Intangible Assets		-10,325,000			-12,219,000
	Discount on Note Payable		-13,825,000			-1,088,000
	Other		-89,000			-69,000
	Total deferred tax liabilities		-24,239,000			-13,376,000
	Net deferred tax assets, excluding net operating loss carryforwards		-13,751,000			-3,472,000
	Net operating loss carryforwards		53,222,000			45,458,000
			39,471,000			41,986,000
	Less valuation allowance		-39,559,000			-42,055,000
	Total deferred tax assets (liabilities)	$	-88,000		$	-69,000
	The following table reflects the change in the valuation allowance for deferred tax assets at December 31:
	Valuation allowance - January 1, 2013	$	38,406,000
	2013 provision		3,649,000
	Valuation allowance - December 31, 2013	$	42,055,000
	Establisment and reversal in 2014 - Convertible Bridge notes		897,000
	Establishment in 2014 - Deerfield note		-13,878,000
	2014 provision		10,485,000
	Valuation allowance - December 31, 2014	$	39,559,000
	The following table presents a reconciliation between the U.S. federal statutory income tax rate and the Company’s effective tax rate:
		2014				2013
	U.S. Federal statutory income tax		35	%			35	%
	State and local income tax, net of benefits		4.9	%			4.4	%
	Fair value of Derivatives		17.1	%			-2.9	%
	Nondeductible guarantee fees		—				-0.9	%
	Impact of changes in rates		-0.2	%			-12.2	%
	Established/reversed tax deferrals (deferred tax liabilities) not thru provision		-68.8	%			-5.5	%
	Other		-1.3	%			—
	Valuation allowance for deferred income tax assets		13.2	%			-18	%
	Effective income tax rate		-0.1	%			-0.1	%
	The Company had loss carry-forwards of approximately $142,701,000 as of December 31, 2014 that may be offset against future taxable income. The carry-forwards will expire between 2021 and 2034. Use of these carry-forwards may be subject to annual limitations based upon previous significant changes in stock ownership. Management has determined that realization of the net deferred tax assets is not assured and accordingly has established a valuation allowance of $39,559,000 and $42,055,000 at December 31, 2014 and 2013, respectively.
	In 2014 and 2013, the Company recorded an income tax provision of approximately $20,000 and $19,000, respectively, related to a deferred tax liability resulting from the amortization of Goodwill for tax purposes. No income tax benefit was recognized in the consolidated statements of operations for stock-based compensation for the years presented due to the Company’s net loss position.
	The Company’s source of income (loss) before income tax provision (benefit) is from both U.S. and foreign sources.
	The Company does not believe it has any uncertain income tax positions as described in its discussion of Income Tax accounting policy in Note 1 – Business and Presentation.

Equity

Equity	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Note 13 — Equity
	Common Stock
	Our common stock has a par value of $.0001 per share. On June 9, 2014, the Company’s shareholders approved an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of all classes of capital stock from 215,000,000 shares to 440,000,000 shares, and the authorized number of common stock from 200,000,000 shares to 425,000,000 shares. Common stock is subordinate to Series A, B, C, and D Convertible Preferred stock. Each share of common stock represents the right to one vote, and common stockholders are entitled to receive dividends as may be declared by the Board of Directors. No dividends were declared or paid on our common stock in 2014 and 2013.
	2014 Private Placement. In March 2014 we raised $2.0 million from the private placement of 3,846,154 shares of common stock (at a price of $0.52 per share) and five-year stock purchase warrants to purchase 2,884,615 shares of common stock at $0.52 per share. As a result of certain non-standard anti-dilution provisions and cash settlement features contained in the warrants, we classified the detachable stock purchase warrants as derivative liabilities, initially at their estimated relative fair value of approximately $1.1 million. We re-measure the warrants to fair value at each balance sheet date. Issuance costs, in the form of warrants and fees, were valued at approximately $136,000 and were recorded to additional paid-in-capital.
	2014 Issuance to Deerfield. In June 2014, we issued 2,709,677 shares of our common stock (with a value of $1.1 million) to Deerfield in satisfaction of certain transaction fees.
	2014 Issuance to former Aldagen Shareholders. In November 2014, we amended and settled our contingent consideration obligations from our 2012 acquisition of Aldagen by issuing 1,270,000 shares of our common stock.
	2014 and 2013 Issuances to Lincoln Park. In February 2013, we entered into a purchase agreement and a registration rights agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Under the terms and subject to the conditions of the agreements, the Company has the right to sell to and Lincoln Park is obligated to purchase up to $15 million in shares of the Company’s common stock, subject to certain limitations, from time to time, over the 30-month period commencing on the date that a registration statement is declared effective by the SEC. The Company may direct Lincoln Park every other business day, at its sole discretion and subject to certain conditions, to purchase up to 150,000 shares of common stock in regular purchases, increasing to amounts of up to 200,000 shares depending upon the closing sale price of the common stock. In addition, the Company may direct Lincoln Park to purchase additional amounts as accelerated purchases if on the date of a regular purchase the closing sale price of the common stock is not below $1.00 per share. The purchase price of shares of common stock related to the future funding will be based on the prevailing market prices of such shares at the time of sales (or over a period of up to 12 business days leading up to such time), but in no event will shares be sold under this arrangement on a day the common stock closing price is less than the floor price of $0.45 per share, subject to adjustment. The Company’s sales of shares of common stock under the agreements are limited to no more than the number of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of more than 9.99% of the then outstanding shares of the Common Stock.
	To date, we have issued 5,250,000 shares to Lincoln Park (raising approximately $2.4 million in gross proceeds) with up to 4,750,000 shares or $12.6 million in shares still available for issuance under this arrangement. In addition to those shares, the Company issued to Lincoln Park 375,000 shares of common stock, and is required to issue up to 375,000 additional shares of common stock, in satisfaction of certain transaction fees. To date we have issued 59,126 shares of common stock in satisfaction of those certain transaction fees. This arrangement expires January 17, 2015.
	2013 Public Offering. In February 2013, the Company issued 9,090,911 shares of the common stock and five-year stock purchase warrants to purchase an additional 6,363,638 shares of common stock (raising $5.0 million or gross proceeds). The purchase price paid by investors was $0.55 for each unit. Each warrant is immediately exercisable at $0.75 per share on or after February 22, 2013 and is subject to transfer restrictions, including among others, compliance with the state securities laws. The warrants are classified in equity.
	In connection with the offering, the Company and the Maryland Venture Fund (Maryland Department of Business and Economic Development) executed an agreement which requires the Company to repurchase MVF’s investment, at MVF’s option, upon certain events outside of the Company’s control. The common stock issued to MVF is classified as “contingently redeemable common shares” in the accompanying consolidated balance sheets.
	The Company paid $402,000 in cash transaction fees to its placement agent, and granted to the placement agent stock purchase warrants to purchase 136,364 shares of common stock. The warrants have the same terms as the investor warrants in this offering, except that the exercise price will be 120% of the exercise price of the investor warrants and may also be exercised on a cashless basis. We also provided the purchasers certain registrations rights.
	2013 Release of the Worden Security Interest in the Licensed Patents. In February 2013, the Company and Charles E. Worden Sr., an individual holder of security interest in patents pursuant to the Substitute Royalty Agreement, dated November 4, 2001 amended that agreement (the “SRA Amendment”) for the purposes of terminating and releasing the security interest and the reversionary interest under the terms of the SRA in exchange for the following consideration: (i) a one-time cash payment of $500,000 (to replace all future minimum monthly royalty payments), (ii) issuance of 250,000 shares of the Company’s common stock (the “Worden Shares”), and (iii) grant of the right to acquire up to 250,000 shares of the Company’s common stock pursuant to a seven-year stock purchase warrant with the exercise price of $0.70 per share. In addition, Mr. Worden’s future annual royalty stream limitation was increased from $600,000 to $625,000. The exercise price and the number of shares issuable upon exercise of the warrant is subject to standard anti-dilution provisions, and contain provisions that are customary for the instruments of this nature, including, among others, a cashless exercise provision. The warrants are classified as equity.
	2013 JP Nevada Trust Note Amendment. In February 2013, the Company amended its note with JP’s Nevada Trust (the “JP Trust Note”) to subordinate the lender’s security interest under the JP Trust Note to that of MidCap. In exchange the Company agreed to (i) extend the maturity date of the JP Trust Note to November 19, 2016 and (ii) expand the lender’s second lien security interest to include the assets of the Company and Aldagen. The parties also agreed to amend the vesting schedule on the lender’s warrants such that the remaining 250,000 warrant shares are exercisable immediately. Finally, the Company agreed to issue the lender a new warrant to purchase up to 266,666 shares at an exercise price of $0.70 per share vesting as follows: (i) 133,333 shares may be exercised only if the JP Trust Note has not been paid by the fourth anniversary of its issuance, and (ii) the remaining 133,333 shares may be exercised only if the JP Trust Note has not been paid by the fifth anniversary of its issuance.
	The Company’s payment obligations with respect to $1.4 million of the JP Trust Note were guaranteed by certain insiders, affiliates, and shareholders of the Company, including David E. Jorden, then Chairman of the Board (the “Guarantors”). In connection with the JP Trust Note amendment, the Company also: (i) approved amendments to the warrant vesting schedule on the Guarantors’ warrants (including those held by Mr. Jorden) issued by the Company in April 2011 such that the remaining 500,000 warrant shares are exercisable immediately and (ii) granted the right to the Guarantors to acquire up to 533,334 shares of the Company’s common stock pursuant to warrants at the exercise price of $0.70 per share, vesting as follows: (i) 266,667 warrant shares may be exercised only if the JP Trust Note has not been prepaid by the fourth anniversary of its issuance, and (ii) the remaining 266,667 shares may be exercised only if the JP Trust Note has not been paid by the fifth anniversary of its issuance (including 107,143 of the previously issued warrants held by Mr. Jorden, which will now vest immediately, and (i) 57,143 of his warrant shares may be exercised only if the JP Trust Note has not been paid by the fourth anniversary of its issuance, and (ii) the remaining 57,143 shares may be exercised only if the JP Trust Note has not been paid by the fifth anniversary of its issuance).
	2013 JMJ Financial Note Amendment and Subordination. In February 2013, the Company amended its notes with JMJ Financial (the “JMJ Notes”), to subordinate JMJ’s rights and remedies under the JMJ Note to that of MidCap. In exchange, the Company extended the maturity date of the JMJ Notes to the later of (i) three years from the effective date of such notes or (ii) the date that is one business day following the date the MidCap loan is paid in full. In addition, JMJ converted $100,000 of the outstanding balance on one of the JMJ Notes into shares of the Company’s common stock and the Company remitted a payment in the amount of $370,000 to partially satisfy one of the JMJ Notes.
	Stock Purchase Warrants
	The Company had the following stock purchase warrants outstanding at December 31:
	Outstanding
	12/31/14	12/31/13				Exercise			Expiration		Classification
						Price
	-			200,000		$	1.5		14-Feb		Equity
	-			800,000		$	0.7		14-Jun		Equity
	-			1,180,547		$	1.42		14-Dec		Equity
	-			2,115,596		$	1.42		14-Dec		Equity
	1,070,916			1,070,916		$	0.51		15-Feb		Equity
	325,000			325,000		$	1.25		15-Feb		Equity
	325,000			325,000		$	1.5		15-Feb		Equity
	325,000			325,000		$	1.75		15-Feb		Equity
	1,295,138			1,295,138		$	0.54		15-Apr		Equity
	100,000			100,000		$	0.37		15-Oct		Equity
	1,488,839			1,488,839		$	0.6		16-Apr		Equity
	916,665			916,665		$	0.5		16-Apr		Equity
	20,000			-		$	0.4		16-Jun		Equity
	136,364			136,364		$	0.66		18-Feb		Equity
	6,363,638			6,363,638		$	0.75		18-Feb		Equity
	5,047,461			5,047,461		$	0.65		18-Dec		Equity*
	232,964			-		$	0.65		18-Dec		Equity
	2,884,615			-		$	0.52		19-Mar		Liability
	1,474,615			-		$	0.52		19-Mar		Liability
	3,525,000			-		$	0.52		19-Jun		Liability
	1,079,137			1,079,137		$	0.7		20-Feb		Equity
	250,000			250,000		$	0.7		20-Feb		Equity
	25,115,384			-		$	0.52		21-Mar		Liability
	67,500,000			-		$	0.52		21-Jun		Liability
	119,475,736			23,019,301
	* These warrants were reclassified to additional paid-in capital as a result of the expiration of non-standard anti-dilution clauses contained within the warrants.
	Certain of the above warrants were issued to consultants in exchange for services provided (see “stock-based compensation” below).
	Stock -Based Compensation
	The Company’s 2002 Long Term Incentive Plan (“LTIP”) and 2013 Equity Incentive Plan (“EIP” and, together with the LTIP, the “Plans”) permit the awards of stock options, stock appreciation rights, restricted stock, phantom stock, performance units, dividend equivalents and other stock-based awards to employees, directors and consultants. We are authorized to issue up to 10,500,000 shares of common stock under the LTIP and up to 18,000,000 shares under the EIP (as approved by our shareholders on June 9, 2014). At December 31, 2014, 2,416,721 and 11,345,852 shares were available to be issued under the LTIP and EIP, respectively.
	To date, the Company has only issued stock options under the Plans. Stock option terms are determined by the Board of Directors for each option grant, and generally vest immediately upon grant or over a period of time ranging up to four years, are exercisable in whole or installments, and expire no longer than ten years from the date of grant. A summary of stock option activity under the Plans as of December 31, 2014, and changes during 2014, is presented below:
								Weighted-
					Weighted-			Average
					Average			Remaining		Aggregate
					Exercise			Contractual		Intrinsic
	Stock Options		Shares		Price			Term		Value
	Outstanding at January 1, 2014		8,520,816		$	1.19
	Granted		8,462,248		$	0.55
	Exercised		0			—
	Forfeited or expired		-2,777,439		$	1.25
	Outstanding at December 31, 2014		14,205,625		$	0.8		7.2		$	2,000
	Exercisable at December 31, 2014		7,298,305		$	1.05		5.3		$	2,000
	The weighted-average grant-date fair value of stock options granted under the Plans during 2014 and 2013 was $0.40 and $0.45, respectively. We granted  8,462,248 and  1,038,000 stock options during 2014 and 2013, respectively; the fair value of stock options granted and vested during 2014 and 2013 was approximately $1,037,000 and $712,000, respectively. No stock options were exercised during 2014 and 2013. As of December 31, 2014, there was approximately $2,400,000 of total unrecognized compensation cost related to non-vested stock options, and that cost is expected to be recognized over a weighted-average period of 2.9 years.   The following table summarizes information about stock options outstanding as of December 31, 2014:
			Options Outstanding							Options Exercisable
					Weighted		Weighted					Weighted
Range of		Number of		Average		Average					Average
Exercise		Outstanding		Remaining		Exercise			Number		Exercise
Prices		Shares		Contract Life		Price			Exercisable		Price
$0.30 - $0.50		3,049,748		8.11		$	0.41		954,164		$	0.43
$0.51 - $0.75		7,721,900		8.4		$	0.6		2,932,999		$	0.6
$0.76 - $1.25		805,000		5.4		$	0.95		805,000		$	0.95
$1.26 - $1.75		1,733,477		3.91		$	1.42		1,732,477		$	1.42
$1.76 - $2.75		825,500		2.42		$	2.32		803,665		$	2.32
$2.76 - $4.50		0		0			—		0			—
$4.51 - $6.00		70,000		1.03		$	5.2		70,000		$	5.2
Additionally, the Company has issued certain stock purchase warrants in exchange for the performance of services, not covered by the Plans. A summary of service provider warrant activity as of December 31, 2014, and changes during 2014, is presented below:
							Weighted-
				Weighted-			Average
				Average			Remaining		Aggregate
				Exercise			Contractual		Intrinsic
Warrants to Service Providers		Shares		Price			Term		Value
Outstanding at January 1, 2014		1,661,364		$	1.24		1.9
Granted		20,000		$	0.4
Exercised		0			—
Forfeited or expired		-200,000		$	1.5
Outstanding at December 31, 2014		1,481,364		$	1.2		1.3		$	0
Exercisable at  December 31, 2014		1,471,364		$	1.2		1.3		$	0
There were 486,364 such warrants granted in 2013, and there were no exercises in 2013.  The following table summarizes information about these warrants outstanding as of December 31, 2014:
		Warrants Outstanding							Warrants Exercisable
				Weighted		Weighted					Weighted
Range of		Number of		Average		Average					Average
Exercise		Outstanding		Remaining		Exercise			Number		Exercise
Prices		Shares		Contract Life		Price			Exercisable		Price
$0.30 - $0.50		120,000		0.9		$	0.38		110,000		$	0.37
$0.51 - $0.75		386,364		4.4		$	0.69		386,364		$	0.69
$0.76 - $1.25		325,000		0.1		$	1.25		325,000		$	1.25
$1.26 - $1.75		650,000		0.1		$	1.63		650,000		$	1.63
As of December 31, 2014, there was approximately $1,000 of total unrecognized compensation cost related to these warrants, which is expected to be recognized over a weighted-average period of 0.5 years.
The Company has recorded stock-based compensation expense as follows:
		Year Ended December 31
Stock-Based Expense		2014			2013
Awards under the 2002 LTIP and 2013 EIP			1,269,150			679,550
Awards outside the equity-based plans			10,145			38,313
		$	1,279,295		$	717,863
Included in Statements of Operations caption as follows:
Salaries and wages		$	1,154,767		$	564,737
Consulting expense			10,145			16,278
General and administrative			114,383			136,848
		$	1,279,295		$	717,863

Supplemental_Cash_Flow_Disclos

Supplemental Cash Flow Disclosures - Non-Cash Transactions	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	Note 14 — Supplemental Cash Flow Disclosures — Non-Cash Transactions
	Non-cash Investing and Financing transactions for years ended December 31 include:
		2014		2013
	Conversion of convertible debt to common stock	$	3,067,423	$	523,927
	Reclassification of the unamortized balance of debt discount and derivative liability, related to the extinguishment and conversion of the subordinated convertible debt, to additional paid-in capital		2,860,627		—
	Derivative liability created from conversion option embedded in Deerfield convertible credit facility		8,825,935		—
	Effect of modification of convertible debt		—		151,032
	Common Stock issued for committed equity financing facility		—		204,015
	Warrants issued for term loan modification		—		151,758
	Warrants issued for term loan		—		568,324
	Common stock and warrants issued for release of security interest in patents		—		325,693
	Warrants issued in connection with convertible debt and equity facility		29,137,682		1,353,842
	Derivative liability for embedded conversion option		—		965,484
	Common stock issued for professional services		—		17,850
	Common stock issued for settlement of contingency		39,150		39,150
	Reclassification of warrant derivative liability to additional paid-in capital as a result of the expiration of non-standard anti-dilution clause contained in warrants		1,331,776		—
	Issuance of common stock in connection with convertible debt facility		1,050,000		—
	Common stock issued to satisfy contingent consideration		127		—
	Accrued property and equipment		64,108		—
	Cash paid for interest was $379,000 and $564,000 in 2014 and 2013, respectively. There were no income taxes paid in 2014 and 2013.

Operating_Leases

Operating Leases	12 Months Ended
	Dec. 31, 2014
Leases, Operating [Abstract]
Leases of Lessee Disclosure [Text Block]	Note 15 — Operating Leases
	The Company leases its office spaces under operating leases with approximate future minimum lease payments as indicated in the table below:
	Years ending December 31:
	2015	$	439,000
	2016		451,000
	2017		463,000
	2018		441,000
	2019		122,000
	Thereafter		—
	Total future minimum lease payments	$	1,916,000
	Our primary office and warehouse facilities are located in Gaithersburg, Maryland, and comprise approximately 12,000 square feet. The facilities fall under two leases with monthly rent, including our share of certain annual operating costs and taxes, at approximately $13,000 and $4,000 per month with the leases expiring September 2019. In addition, we lease a 2,076 square foot facility in Nashville, Tennessee which is being utilized as a commercial operations. The lease is approximately $4,000 per month excluding our shares of annual operating expenses and expires April 30, 2018. We also lease a 16,300 square foot facility located in Durham, North Carolina. This facility falls under one lease with monthly rent, including our share of certain annual operating costs and taxes, at approximately $20,000 per month with the lease expiring December 31, 2018. As a result of our discontinuance of the ALD-401 clinical trial, the Company ceased use of the facility in Durham, North Carolina on July 31, 2014 and sublet the facility beginning August 1, 2014. The sublease rent is approximately $13,000 per month and expires December 31, 2018.
	For the years ended December 31, 2014 and 2013, the Company incurred rent expense of approximately $515,000 and $324,000, respectively. In 2014 we recorded rent expense of approximately $242,000 for a loss on the abandonment of lease as a result of our discontinued use and following sublet of the Durham, North Carolina facility.

Geographic_Concentration_Infor

Geographic Concentration Information	12 Months Ended
	Dec. 31, 2014
Geographic Areas, Revenues from External Customers [Abstract]
Geographic Information On Revenues [Text Block]	Note 16 — Geographic Concentration Information
	Product sales consist of the following:
		Year Ended December 31,
		2014		2013
	Revenue from U.S. product sales	$	4,273,181	$	9,549,015
	Revenue from non-U.S. product sales		1,576,149		949,711
	Total revenue from product sales	$	5,849,330	$	10,498,726

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 17 — Commitments and Contingencies
	Series A Preferred stock contingency
	Under the Company’s plan of reorganization upon emergence from bankruptcy in July 2002, the Series A Preferred stock and the dividends accrued thereon that existed prior to emergence from bankruptcy were to be exchanged into one share of new common stock for every five shares of Series A Preferred stock held as of the date of emergence from bankruptcy. This exchange was contingent on the Company’s attaining aggregate gross revenues for four consecutive quarters of at least $10,000,000 and if met would result in the issuance of 325,000 shares of the Company’s common stock. The Company reached such aggregate revenue levels as of the end of the quarter ended June 30, 2012. As of December 31, 2014, 271,000 common stock issuable remain.
	Aldagen Contingent Consideration
	Aldagen’s former investors had the right to receive up to 20,309,723 shares of our common stock, contingent upon the achievement of certain milestones related to the current ALD-401 Phase 2 clinical trial.
	Under the terms of the February 2013 amendment to the Exchange and Purchase Agreement by and among Nuo Therapeutics, Inc., Aldagen, Inc. and Aldagen Holdings, LLC, the parties to the agreement modified the terms of the post-closing contingent consideration under the terms of the original agreement. Following and as a result of the amendment, Nuo Therapeutics recognized approximately $1,006,000 as operating expense with the offset to equity for the period ended December 31, 2013.
	On November 11, 2014, the Company and Aldagen Holdings, LLC, executed that certain Second Amendment to the February 8, 2012 Exchange and Purchase Agreement, as amended on February 8, 2013 (as amended to date, the “Exchange Agreement”). Pursuant to the terms of the Second Amendment, the terms of the post-closing consideration originally contemplated under the Exchange Agreement and structured around the achievement of certain milestone events relating to the Company’s ALD-401 Phase 2 clinical trials were amended such that, in full satisfaction of all the post-closing issuance obligations of the Company to Aldagen Holdings, the Company agreed to a one-time issuance of 1,270,000 shares of Nuo Therapeutics common stock, out of the 20,309,723 shares of our common stock held in reserve, which were contingently issuable upon the achievement of certain milestones related to the current ALD-401 Phase 2 clinical trial.
	Deerfield Registration Rights Agreement
	On March 31, 2014, we entered into a Registration Rights Agreement (the “RRA”) with Deerfield investors pursuant to the terms and provisions of the March 31, 2014 Facility Agreement and agreed to register, among others, shares of our common stock issuable upon conversion and exercise of convertible notes and related common stock warrants sold in the March 31 and June 30 Deerfield financings. At the time of the closing of the March 31st draw, we issued to Deerfield warrants to purchase 25,115,384 shares of the Company’s common stock at an exercise price of $0.52 per share; at the time of the June 25th draw - warrants to purchase 67,500,000 shares of the Company’s common stock at an exercise price of $0.52 per share. The maximum number of shares of our common stock that can be issued pursuant to the conversion of the Deerfield facility is 67,307,692 shares; the maximum number of shares of our common stock that can be issued pursuant to the terms of the Deerfield warrants is 92,615,385 shares. In accordance with the RRA, we are obligated to file and maintain an effective registration statement, all in accordance with the terms of the RRA until the date when all shares underlying the convertible notes and related warrants (and any other securities issued or issuable with respect to in exchange for such shares) have been sold or at any time following the six month anniversary of the date of issuance, all warrant shares issuable upon exercise of the warrants should be eligible for immediate resale pursuant to Rule 144 under the Securities Act.
	FDA clearance
	In conjunction with its FDA clearance, we agreed to conduct a post-market surveillance study to further analyze the safety profile of bovine thrombin as used in the Aurix ™ System. This study was estimated to cost between $500,000 and $700,000 over a period of several years, which began in the third quarter of 2008. As of December 31, 2014, approximately $368,000 had been incurred. Since the inception of this study, we have enrolled 120 patients, noting no adverse events. Based on the additional positive safety data, we suspended further enrollment in this study pending further discussion with the FDA.
	Letter of Credit
	In July 2009, in satisfaction of a Maryland law pertaining to Wholesale Distributor Permits, we established a Letter of Credit, in the amount of $50,000, naming the Maryland Board of Pharmacy as the beneficiary. This Letter of Credit serves as security for the performance by the Company of its obligations under applicable Maryland law regarding this permit and is collateralized by a Certificate of Deposit (“CD”) purchased from our commercial bank. This CD bears interest at an annual rate of 0.10% and matures on June 24, 2015.
	MVF Stock Repurchase Agreement
	The Company and the MVF, in compliance with MVF’s investment policies, agreed to execute a certain Stock Repurchase Agreement which requires us to repurchase the MVF’s investment, at MVF’s option, upon certain events outside of our control; provided, however, that in the event that, at the time of either such event our securities are listed on a national securities exchange, the foregoing repurchase will not be triggered. The common shares issued to MVF are classified as “conditionally redeemable common stock” in the accompanying consolidated balance sheet. The value of the warrants and offering expenses allocable to the contingently redeemable common shares was not material. Upon the termination of the stock repurchase agreement or the sale of the stock by MVF, the temporary equity will be re-classed to permanent equity.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 18 — Subsequent Events
	In September 2009, we entered into a license and distribution agreement with Millennia Holdings, Inc. (“Millennia”) for the Company’s Aurix System in Japan. Since then, Millennia has been collecting and publishing clinical data for regulatory purposes and expanding the utilization of Aurix throughout their network. The diabetic population in Japan is estimated to be approximately seven million adults. Millennia has assisted the Company in securing a partner to address widespread distribution in Japan. In January 2015 we granted to Rohto Pharmaceutical Co., Ltd. (“Rohto”) a royalty bearing, nontransferable, exclusive license, with limited right to sublicense, to use certain of the Company’s intellectual property for the development, import, use, manufacturing, marketing, sale and distribution for all wound care and topical dermatology applications of the Aurix system and related intellectual property and know-how in human and veterinary medicine in Japan in exchange for an upfront payment from Rohto of $3.0 million (which is reduced by the $1.5 million payment to Millennia Holdings, as set forth below). The agreement also contemplates additional royalty payments based on the net sales of Aurix in Japan and an additional future cash payment in the event specific milestones are met. In connection with and effective as of the entering into the Rohto Agreement, we executed Amendment No. 5 to the Licensing and Distribution Agreement with Millennia dated September 10, 2009, as subsequently amended to terminate the Millennia Agreement and to allow us to transfer the exclusivity rights from Millennia to Rohto. In connection with this amendment we paid a one-time, non-refundable fee of $1.5 million to Millennia upon our receipt of the $3.0 million upfront payment from Rohto and may be required to pay certain future royalty payments to Millennia based upon net sales in Japan. Millennia has been instrumental in establishing the advanced wound care market in Japan, and will continue to work with Rohto to develop the market for Aurix. Further, Rohto has assumed all responsibility for securing the Marketing Authorization (“MA”) from Japan’s Ministry of Health, Labour and Welfare (“MHLW”), while we will provide relevant product information, as well as clinical and other data to support Rohto’s MA application.

Business_and_Presentation_Poli

Business and Presentation (Policies)	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Policy Text Block]	Description of Business
	At our 2014 Annual Meeting, our shareholders voted to approve the name change amendment to our Certificate of Incorporation. The new name of our Company is “Nuo Therapeutics, Inc.” and the name change was effective upon filing of the Certificate of Amendment to our Certificate of Incorporation in the State of Delaware. Nuo Therapeutics, Inc., formerly Cytomedix, Inc., (“Nuo Therapeutics,” the “Company,” “we,” “us,” or “our”) is a biomedical company marketing products within the U.S. and internationally. We commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The use of autologous from self-biological therapies for tissue repair and regeneration is part of a transformative clinical strategy designed to improve long term recovery in complex chronic conditions with significant unmet medical needs. Growth drivers in the U.S. include Medicare coverage for the treatment of chronic wounds under a National Coverage Determination when registry data is collected under Coverage with Evidence Development (“CED”), and a worldwide distribution and licensing agreement that allows our partner to promote the Angel System for all uses other than wound care.
	Our current commercial offerings consist of point of care technologies for the safe and efficient separation of autologous blood and bone marrow to produce platelet based therapies or cell concentrates. We currently have two distinct platelet rich plasma (“PRP”) devices, the Aurix™  System (formerly known as the AutoloGelTM System) for wound care and the Angel ™ concentrated Platelet Rich Plasma (“cPRP”) System for orthopedics markets. Approximately 73% of our sales are in the United States, where we sell our products through direct sales representatives and distributors. Since August 8, 2013, Arthrex, Inc. (“Arthrex”), as our exclusive distributor for Angel, accounted for 100% of our Angel sales.
	Since our inception, we have financed our operations by raising debt, issuing equity and equity-linked instruments, licensing arrangements, royalties, and product revenues. We have incurred, and continue to incur, recurring losses and negative cash flows. On March 31, 2014, we entered into a $35,000,000 convertible debt facility, $9,000,000 of which was funded on March 31, 2014 and the remaining $26,000,000 was funded on June 25, 2014. In addition, on March 31, 2014 we raised $2.0 million of gross proceeds from the sale of our common stock and warrants to an accredited investor (See Note 11 – Debt and Note 13 - Equity for additional details.) We used approximately $5.9 million of the net proceeds from these transactions to retire outstanding debt and interest, approximately $0.3 million to repay a portion of previously outstanding convertible debt and interest, and we converted approximately $3.1 million previously outstanding convertible debt and interest into common stock (See Note 11 - Debt for additional details.)
	At December 31, 2014, we had approximately $15.9 million of cash on hand. Our operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, lack of operating history and uncertainty of future profitability and possible fluctuations in financial results. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. We believe that our current resources, expected revenue from current products, including additional revenue expected to be generated from our increased marketing efforts, royalty revenue and license fee revenue will be adequate to maintain our operations through at least the end of 2015. Accordingly, management believes the going-concern basis is appropriate for the accompanying consolidated financial statements.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In our opinion, the accompanying consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. Certain prior period information has been reclassified to conform to the current period presentation.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned and controlled subsidiary. All significant inter-company accounts and transactions are eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, allowance for doubtful accounts, valuation of derivative liabilities, valuation and probability of contingent liabilities, fair value of long-lived assets, deferred taxes and associated valuation allowance, and the depreciable lives of fixed assets (including intangible assets and goodwill). Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents
	We consider all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents.
	In connection with the Deerfield Facility Agreement (See Note 7 - Debt for additional details), the Company is required to maintain a compensating cash balance of $5,000,000 in deposit accounts subject to control agreements in favor of the lenders.
	Approximately $15,486,000 and $2,667,000 held in financial institutions was in excess of FDIC insurance at December 31, 2014 and 2013 respectively.
Receivables, Policy [Policy Text Block]	Accounts Receivable and Credit Concentration
	We generate accounts receivable from the sale of our products. Our trade receivables balance at December 31, 2014 was primarily from Arthrex (64%). In addition, Arthrex accounted for 91% and 47% of total products sales in 2014 and 2013, respectively. No other single customer accounted for more than 5% of total product sales.
	We provide for a reserve against receivables for estimated losses that may result from a customer’s inability or unwillingness to pay. The allowance for doubtful accounts is estimated primarily based upon historical write-off percentages, known problem accounts, and current economic conditions. Accounts are written off against the allowance for doubtful accounts when we determine that amounts are not collectable. Recoveries of previously written-off accounts are recorded when collected. At December 31, 2014 and December 31, 2013, we maintained an allowance for doubtful accounts of $32,000 and $16,000, respectively.
	We use single suppliers for several components of the Angel and Aurix™ product lines. We outsource the manufacturing of various products, including component parts for Angel, to contract manufacturers. While we believe these manufacturers to demonstrate competency, reliability and stability, there is no assurance that one or more of them will not experience an interruption or inability to provide us with the products needed to satisfy customer demand. Additionally, while most of the components of Aurix™ are generally readily available on the open market, a reagent, bovine thrombin, is available exclusively through Pfizer, with whom we have an established vendor relationship.
	During 2014 and 2015, we devoted substantial resources to enhancing and improving the Angel Product Line to meet new and additional regulatory requirements. During the period that we have been implementing the modifications, we were unable to meet our customer’s demand for Angel devices. As a result, our sales were lower than expected and in addition, we incurred a charge to earnings of $600,000 during the year ended December 31, 2014, reflecting our expected costs for refurbishment and design improvements for the units in circulation. Although we believe that we have completed all the necessary design modifications to the Angel Products, we cannot be sure that we will not continue to experience delays and additional costs in the future.
Inventory, Policy [Policy Text Block]	Inventory
	The Company’s inventory is produced by third party manufacturers and consists primarily of finished goods. Inventory cost is determined on a first-in, first-out basis and is stated at the lower of cost or net realizable value. The Company maintains an inventory of kits, reagents, and other disposables that have shelf lives that generally range from 18 months to five years. We provide for a reserve against inventory for estimated losses that may result in excess and obsolete inventory (i.e. from the expiration of products).
	The Company’s reserve for expired inventory is estimated based upon the inventory’s remaining shelf life and our anticipated ability to sell such inventory, which is estimated utilizing historical usage and future forecasts, within its remaining shelf life. At December 31, 2014 and 2013 the Company maintained a reserve for expired and excess and obsolete inventory of $90,000 and $0, respectively. Expired products are segregated and used for demonstration purposes only; the Company records the associated expense for this reserve to cost of sales on the consolidated statement of operations.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment
	Property and equipment is stated at cost less accumulated depreciation and is depreciated, using the straight-line method, over its estimated useful life ranging from three to five years for all assets except for furniture, lab, and manufacturing equipment which is depreciated over seven and ten years, respectively. Leasehold improvements are stated at cost less accumulated depreciation and is depreciated, using the straight-line method, over the lesser of the expected lease term or its estimated useful life ranging from three to six years. Amortization of leasehold improvements is included in depreciation expense. Maintenance and repairs are charged to operations as incurred. When assets are disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in other income (expense).
	Centrifuges may be sold, leased, or placed at no charge with customers. Depreciation expense for centrifuges that are available for sale, leased, or placed at no charge with customers are charged to cost of sales. Angel centrifuges are sold directly to our worldwide distributor, Arthrex, and unless used for internal purposes, no longer recorded as property and equipment. When Angel centrifuges were sold to Arthrex for the year ended 2013, the net book value was charged to cost of sales. Depreciation expense for centrifuges used for sales and marketing and other internal purposes are charged to operations.
	Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets.
Exit Activities [Policy Text Block]	Exit Activities
	On May 5, 2014, we announced preliminary efficacy and safety results of our RECOVER-Stroke Phase 2 clinical trial in patients with neurological damage arising from ischemic stroke and treated with ALD-401. Observed improvements in the primary endpoint (mean modified Rankin Score or mRS) of the trial were not clinically or statistically significant. In light of this outcome, we discontinued further funding of the ALD-401 development program, decided to close our facilities in Durham, NC, and terminated certain employees.
	The discontinuance of this development program is considered an exit activity. As such, we recognized the following expenses in the second and third quarters of 2014:
		Quarter ended
		June 30, 2014		September 30, 2014
	Severance costs	$	320,000	$	-
	Loss on abandonment of lease		-		243,000
	Loss on disposal of assets		-		132,000
	Total	$	320,000	$	375,000
	An accrual of approximately  $413,000 for the loss on abandonment of the lease, remained at December 31, 2014. The accrued loss will be amortized over the life of the lease against future rental payments made and sublet income payments received. Severance expense is classified as “salaries and wages” and the loss on abandonment and loss on disposal of assets is classified in “Other income (expense) Loss on disposal of fixed assets” in the accompanying consolidated statements of operations. The accrued loss on abandonment is included in accrued expenses and other liabilities in the accompanying  consolidated balance sheets.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible Assets and Goodwill
	Intangible assets were acquired as part of our acquisition of the Angel business and Aldagen, and consist of definite-lived and indefinite-lived intangible assets, including goodwill.
	Definite-lived intangible assets
	Our definite-lived intangible assets include trademarks, technology (including patents) and customer relationships, and are amortized over their useful lives and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, we test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), we would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. We periodically reevaluate the useful lives for these intangible assets to determine whether events and circumstances warrant a revision in their remaining useful lives. During the second quarter of 2014, as a result of recent events and changes in circumstances, the Company performed an assessment of our trademarks and concluded that the carrying value of the trademarks was impaired. (See Note 8 — Goodwill and Identifiable Intangible Assets for additional details.)
	Indefinite-lived intangible assets
	We evaluate our indefinite-lived intangible asset, consisting solely of in-process research and development (“IPR&D”) acquired in the Aldagen acquisition, for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and at least on an annual basis on October 1 of each year, by comparing the fair value of the asset with its carrying amount. If the carrying amount of the intangible asset exceeds its fair value, we would recognize an impairment loss in the amount of that excess. During the second quarter of 2014 the Company performed an assessment of our IPR&D as of June 30, 2014, as a result of recent events and changes in circumstances, and concluded that the carrying value of the IPR&D was impaired. Our annual impairment evaluation of indefinite lived intangible assets was performed as of October 1, 2014, and it was determined that there was no additional impairment of the recorded balances. (See Note 8 — Goodwill and Identifiable Intangible Assets for additional details.)
	Goodwill
	Goodwill represents the purchase price of acquisitions in excess of the amounts assigned to acquired tangible or intangible assets and assumed liabilities. Amounts allocated to goodwill are tax deductible in all relevant jurisdictions. As a result of our acquisition of Aldagen in February 2012, we recorded goodwill of approximately $422,000. Prior to the acquisition of Aldagen, we had goodwill of approximately $707,000 as a result of the acquisition of the Angel business in April 2010.
	We conduct an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value impaired. The Company conducted an impairment test of our Goodwill as of June 30, 2014, as a result of recent events and changes in circumstances, and concluded that Goodwill was not impaired. (See Note 5 — Goodwill and Intangible Assets for additional details.) The Company also conducted an impairment test of our Goodwill as of October 1, 2014, and concluded that Goodwill was not impaired.
Conditionally Redeemable Common Stock, Policy [Policy Text Block]	Conditionally Redeemable Common Stock
	The Maryland Venture Fund (“MVF,” part of Maryland Department of Business and Economic Development) has an investment in our common stock, and can require us to repurchase the common stock, at MVF’s option, upon certain events outside of our control; provided, however, that in the event that, at the time of either such event our securities are listed on a national securities exchange, the foregoing repurchase will not be triggered. MVF’s common stock are classified as “contingently redeemable common shares” in the accompanying consolidated balance sheets.
Income Tax, Policy [Policy Text Block]	Income Taxes
	The Company accounts for income taxes using the asset and liability method. Under the asset and liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted.
	For the year ended December 31, 2014, the income tax provision relates exclusively to a deferred tax liability associated with the amortization of goodwill. The Company has analyzed filing positions in all of the federal and state jurisdictions where it is required to file income tax returns, as well as all open tax years in these jurisdictions. All tax years are subject to examination for the Company’s federal return due to our net operating loss carry-forward. The Company believes that its income tax filing positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded.
	The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income before taxes. There were no such items for 2014 and 2013.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	We recognize revenue when the four basic criteria for recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) consideration is fixed or determinable; and (4) collectability is reasonably assured.
	Sales of products
	We provide for the sale of our products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recognized upon shipment of products to the customers. We do not maintain a reserve for returned products as in the past those returns have not been material and are not expected to be material in the future.
	Usage or leasing of blood separation equipment
	As a result of the acquisition of the Angel ™ business in 2010, we acquired various multiple element revenue arrangements that combine the (i) usage or leasing of blood separation processing equipment, (ii) maintenance of processing equipment, and (iii) purchase of disposable processing sets and supplies. We assigned these multiple element revenue arrangements to Arthrex on August 7, 2013. (See Note 3 — Distribution and License Agreement with Arthrex for additional details.) Under these arrangements, the total arrangement consideration was allocated to the various elements based on their relative estimated selling prices. The usage of the blood separation processing equipment was accounted for as an operating lease; since customer payments were contingent upon the customer ordering new products, rental income was recorded following the contingent rental method when rental income was earned and collectability was reasonably assured. The sale of disposable processing sets and supplies and maintenance were deemed a combined unit of accounting; since (a) any consideration for disposable processing sets and supplies and maintenance was contingent upon the customer ordering additional disposable processing sets and supplies and (b) both the disposable products and maintenance services were provided over the same term, we recognized revenue for this combined unit of accounting following the contingent revenue method at the time disposable products were delivered based on prices contained in the agreement.
	Percentage-based fees on licensee sales of covered products are generally recorded as products are sold by licensees and are reflected as “Royalties” in the consolidated statements of operations. Direct costs associated with product sales and royalty revenues are recorded at the time that revenue is recognized.
	Deferred revenue at December 31, 2014 consists of prepaid licensing revenue of approximately $1,442,000. Revenue of approximately $402,000 related to the prepaid license was recognized during the year ended December 31, 2014. On January 1, 2013 a medical device excise tax came into effect that required manufacturers to pay tax of 2.3% on the sale of certain medical devices. We report the medical device excise tax on a gross basis, recognizing the tax as both revenue and cost of sales.
Segment Reporting, Policy [Policy Text Block]	Segments and Geographic Information
	We operate in one business segment. Approximately 27% and 9% of our product sales were generated outside of the United States for the years ended December 31, 2014 and 2013, respectively.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses
	Research and development costs are expensed as incurred and primarily consist of expenses relating to product development. Research and development costs do not include salaries and wages, which are included in “Salaries and Wages” in the Consolidated Statements of Operations, and the allocation of overhead and other indirect costs, which are included in the “Consulting expenses” and “General and Administrative expenses” lines in the Consolidated Statements of Operations.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation
	The Company, from time to time, may issue stock options or stock awards to employees, directors, consultants, and other service providers under its 2002 Long-Term Incentive Plan (“LTIP”) or 2013 Equity Incentive Plan (“EIP”). In some cases, it has issued compensatory warrants to service providers outside the LTIP or EIP (See Note 13 – Equity for additional details).
	All equity-based compensation is estimated on the issuance date of grant using the Black-Scholes-Merton option-pricing formula. The assumptions used in the model for the LTIP and EIP are summarized in the following table:
		2014		2013
	Risk free rate	0.1-1.7	%	0.4-1.4	%
	Weighted average expected years until exercise	6.3		5.9
	Expected stock volatility	118-127	%	96-135	%
	Dividend yield	—		—
	For stock options, expected volatilities are based on historical volatility of the Company’s stock. Company data was utilized to estimate option exercises and employee terminations within the valuation model for the year ended December 31, 2014 and peer company data to estimate option exercises and employee terminations within the valuation model for the year ended December 31, 2013. Expected years until exercise represents the period of time that options are expected to be outstanding. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The Company estimated that the dividend rate on its Common stock will be zero.
	The fair value of stock options or compensatory warrants issued to service providers utilizes the same methodology with the exception of the expected term. For these awards to non-employees, the Company estimates that the options or warrants will be held for the full term.
	Stock-based compensation for awards granted to non-employees is periodically remeasured as the underlying options and warrants vest. The Company recognizes an expense for such awards throughout the performance period as the services are provided by the non-employees, based on the fair value of these options and warrants at each reporting period.
	The Company estimates the fair value of stock awards based on the closing market value of the Company’s stock on the date of grant.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Earnings (Loss) per Share
	Basic earnings (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of shares of common stock outstanding during the period.
	For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.
	For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The total number of anti-dilutive shares, common stock options, warrants exercisable for common stock, convertible preferred stock and convertible debt, which have been excluded from the computation of diluted earnings (loss) per share, were 200,989,054 and 61,134,957 for the years ended December 31, 2014 and 2013, respectively.
Defined Contribution Plan [Policy Text Block]	Defined Contribution Plans
	The Company sponsors a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time U.S. employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. Participants are always fully vested in their contributions. The Company makes employer matching contributions, which also vest immediately. This plan is designated as a “Safe Harbor” plan. During 2014 and 2013, the Company contributed approximately $175,000 and $164,000 in cash to the plan.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” The Financial Accounting Standards Board (FASB or Board) and the International Accounting Standards Board (IASB) (collectively, the Boards) jointly issued a long-awaited standard that will supersede virtually all of the revenue recognition guidance in U.S. GAAP. The FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606). The FASB has set an effective date of fiscal years beginning after December 15, 2016. Early adoption is not permitted for public entities. FASB ASU No. 2014-09 will amend FASB Accounting Standards Codification™ (ASC) by creating Topic 606, Revenue from Contracts with Customers and Subtopic 340-40, Other Assets and Deferred Costs—Contracts with Customers. This document reorganizes the guidance contained in FASB ASC 606 (revenue recognition standard), to follow the five step revenue recognition model along with other guidance impacted by this standard. The potential effects of the adoption of ASU 2014-09, Topic 606 on our results of operations and the Company’s consolidated financial statements have not been determined at this time.
	ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40) - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Previously, there was no guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. FASB issued ASU 2014-15 to provide guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact, if any, that the adoption will have on its consolidated financial statements.
	ASU No. 2014-16, “Derivatives and Hedging (Topic 815) – Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity.” There are predominantly two methods used in current practice by issuers and investors in evaluating whether the nature of the host contract within a hybrid financial instrument issued in the form of a share is more akin to debt or to equity. Additionally, there is diversity in practice with respect to the consideration of redemption features in relation to other features when determining whether the nature of a host contract is more akin to debt or to equity. The objective of this update is to eliminate the use of different methods in practice and thereby reduce existing diversity under GAAP in the accounting for hybrid financial instruments issued in the form of a share. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption, including adoption in an interim period, is permitted. If an entity early adopts the amendments in an interim period, any adjustments shall be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact, if any, that the adoption will have on its consolidated financial statements.

Business_and_Presentation_Tabl

Business and Presentation (Tables)	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Exit Activities [Table Text Block]	The discontinuance of this development program is considered an exit activity. As such, we recognized the following expenses in the second and third quarters of 2014:
		Quarter ended
		June 30, 2014		September 30, 2014
	Severance costs	$	320,000	$	-
	Loss on abandonment of lease		-		243,000
	Loss on disposal of assets		-		132,000
	Total	$	320,000	$	375,000
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The assumptions used in the model for the LTIP and EIP are summarized in the following table:
		2014		2013
	Risk free rate	0.1-1.7	%	0.4-1.4	%
	Weighted average expected years until exercise	6.3		5.9
	Expected stock volatility	118-127	%	96-135	%
	Dividend yield	—		—

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Schedule Of Financial Assets And Liabilities At Fair Value [Table Text Block]	The following table represents the fair value hierarchy for our financial assets and liabilities measured at fair value on a recurring basis for the year ended December 31, 2014 and 2013:
		As of December 31, 2014
	Description	Level 1		Level 2		Level 3		Total
	Assets
	Investment in money market funds	$	15,736,350	$	-	$	-	$	15,736,350
	Total investment in money market funds	$	15,736,350	$	-	$	-	$	15,736,350
	Liabilities
	Embedded conversion options	$	-	$	-	$	4,362,225	$	4,362,225
	Stock purchase warrants		-		-		25,484,596		25,484,596
	Total derivative liabilities	$	-	$	-	$	29,846,821	$	29,846,821
		As of December 31, 2013
		Level 1		Level 2		Level 3		Total
	Assets
	Investment in money market funds	$	2,303,556	$	-	$	-	$	2,303,556
	Total investment in money market funds	$	2,303,556	$	-	$	-	$	2,303,556
	Liabilities
	Embedded conversion options	$	-	$	-	$	1,515,540	$	1,515,540
	Stock purchase warrants		-		-		1,733,055		1,733,055
	Total derivative liabilities	$	-	$	-	$	3,248,595	$	3,248,595
Fair Value, Measurement Inputs, Disclosure [Table Text Block]	The following tables set forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the year ended December 31, 2014 and 2013:
		Balance at				Modification		Effect of						Balance at
		January 1,		Established in		of Convertible		Conversion to		Change in		Reclass to		December 31,
	Description	2014		2014		Debt Agreement		Common Stock		Fair Value		Equity (1)		2014
	Derivative liabilities:
	Embedded conversion options	$	1,515,540	$	8,825,935	$	-	$	-1,932,693	$	-4,046,557	$	-	$	4,362,225
	Stock purchase warrants		1,733,055		29,137,682		-		-		-4,054,365		-1,331,776		25,484,596
		Balance at				Modification								Balance at
		January 1,		Established in		of Convertible		Conversion to		Change in		Reclass to		December 31,
	Description	2013		2013		Debt Agreement		Common Stock		Fair Value		Equity		2013
	Derivative liabilities:
	Embedded conversion options	$	780,960	$	965,484	$	250,361	$	-393,948	$	90,839	$	-178,156	$	1,515,540
	Stock purchase warrants		-		1,353,842		-		-		379,213		-		1,733,055
	(1) Various warrants were reclassified to additional paid-in capital as a result of the expiration of non-standard anti-dilution clauses contained within the warrants.
Schedule of Impaired Intangible Assets [Table Text Block]	The following table represents the fair value hierarchy for our non-financial assets that were measured during 2014 (we did not remeasure any of our non-financial assets during 2013):
		Level 1		Level 2		Level 3		Total
	Intangible assets
	Intangible assets - IPR&D	$	—	$	—	$	25,926,000	$	25,926,000
	Intangible assets - Trademarks		—		—		706,229		706,229
	Total	$	—	$	—	$	26,632,229	$	26,632,229

Receivables_Tables

Receivables (Tables)	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	Accounts and royalties receivable, net consisted of the following:
		December 31,		December 31,
		2014		2013
	Trade receivables	$	609,179	$	2,449,199
	Other receivables		1,312,617		1,493,979
			1,921,796		3,943,178
	Less allowance for doubtful accounts		-32,469		-16,497
		$	1,889,327	$	3,926,681
Schedule Of Change In Allowance For Doubtful Accounts [Table Text Block]	The following table reflects the approximate change in allowance for doubtful accounts.
		Balance at		Charged to				Balance at
		Beginning of		Costs and		Balances		End of
		Period		Expenses		charged-off		Period
	Year Ended December 31, 2014
	Allowance for doubtful accounts	$	16,497	$	31,773	$	-15,801	$	32,469
	Year Ended December 31, 2013
	Allowance for doubtful accounts	$	42,709	$	75,166	$	-101,378	$	16,497

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory, net consisted of the following:
		December 31,		December 31,
		2014		2013
	Raw materials	$	121,631	$	125,583
	Finished goods		524,989		985,924
			646,620		1,111,507
	Less provision for inventory obsolescence		-90,000		—
		$	556,620	$	1,111,507

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Prepaid Expense and Other Assets, Current [Abstract]
Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]	Prepaid expenses and other current assets consisted of the following:
		December 31,		December 31,
		2014		2013
	Prepaid insurance	$	125,106	$	63,096
	Prepaid fees and rent		249,046		151,454
	Deposits and advances		1,360,672	$	279,870
	Prepaid royalties		604,166		724,999
	Other Current Assets		—		38,863
		$	2,338,990	$	1,258,282

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property Plant And Equipments [Table Text Block]	Property and equipment, net consisted of the following:
		December 31,		December 31,
		2014		2013
	Medical equipment	$	801,463	$	1,278,681
	Office equipment		150,411		86,001
	Software		307,844		—
	Manufacturing equipment		307,851		307,971
	Leasehold improvements		32,130		390,911
			1,599,699		2,063,564
	Less accumulated depreciation and amortization		-674,528		-1,144,095
		$	925,171	$	919,469

Goodwill_and_Identifiable_Inta1

Goodwill and Identifiable Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill [Table Text Block]	The carrying value of our intangible assets, and the associated amortization, were as follows:
		December 31,		December 31,
		2014		2013
	Trademarks	$	1,047,000	$	2,310,000
	Technology		2,355,000		2,355,000
	Customer relationships		708,000		708,000
	In-process research and development		25,926,000		29,585,000
	Total	$	30,036,000	$	34,958,000
	Less accumulated amortization		-1,288,230		-1,189,046
		$	28,747,770	$	33,768,954
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Annual amortization expense based on our existing intangible assets and their estimated useful lives is expected to be approximately:
	2015	308,400
	2016	308,400
	2017	308,400
	2018	242,000
	2019	219,900
	Thereafter	1,434,800

Accrued_expenses_Tables

Accrued expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consisted of the following:
		December 31,		December 31,
		2014		2013
	Customer deposits		2,516,202		1,795,803
	Accrued compensation and benefits		984,227		795,584
	Other payables		379,019		242,993
	Accrued interest		1,025,623		2,250
	Due to Arthrex		324,531		1,630,564
	Accrued professional fees		285,446		199,634
	Accrued loss on abandonment of lease, current portion		103,176		—
	Accrued Angel machine refurbishment costs		600,000		—
		$	6,218,224	$	4,666,828

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Income tax (expense) benefit for the years ended December 31, 2014 and 2013 consisted of the following:
		2014			2013
	Current:
	Federal	$	—		$	—
	State		—			—
	Deferred:
	Federal		9,513,282			-212,022
	State		952,533			-401,215
	Net operating loss carryforward		7,764,117			4,243,885
	Valuation Allowance		-18,249,516			-3,649,237
	Total income tax (expense) benefit	$	-19,584		$	-18,589
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Significant components of Nuo Therapeutics’ deferred tax assets and liabilities consisted of the following at December 31:
		2014			2013
	Deferred tax assets:
	Stock-based compensation	$	5,942,000		$	5,371,000
	Tax credits		3,162,000			2,895,000
	Deferred revenue		575,000			861,000
	Start-up and organizational costs		276,000			272,000
	Tax deductible Goodwill		88,000			112,000
	Property and equipment		56,000			240,000
	Other		389,000			153,000
	Total deferred tax assets		10,488,000			9,904,000
	Deferred tax liabilities:
	Intangible Assets		-10,325,000			-12,219,000
	Discount on Note Payable		-13,825,000			-1,088,000
	Other		-89,000			-69,000
	Total deferred tax liabilities		-24,239,000			-13,376,000
	Net deferred tax assets, excluding net operating loss carryforwards		-13,751,000			-3,472,000
	Net operating loss carryforwards		53,222,000			45,458,000
			39,471,000			41,986,000
	Less valuation allowance		-39,559,000			-42,055,000
	Total deferred tax assets (liabilities)	$	-88,000		$	-69,000
Schedule Of Change In Valuation Allowance For Deferred Tax Assets [Table Text Block]	The following table reflects the change in the valuation allowance for deferred tax assets at December 31:
	Valuation allowance - January 1, 2013	$	38,406,000
	2013 provision		3,649,000
	Valuation allowance - December 31, 2013	$	42,055,000
	Establisment and reversal in 2014 - Convertible Bridge notes		897,000
	Establishment in 2014 - Deerfield note		-13,878,000
	2014 provision		10,485,000
	Valuation allowance - December 31, 2014	$	39,559,000
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The following table presents a reconciliation between the U.S. federal statutory income tax rate and the Company’s effective tax rate:
		2014				2013
	U.S. Federal statutory income tax		35	%			35	%
	State and local income tax, net of benefits		4.9	%			4.4	%
	Fair value of Derivatives		17.1	%			-2.9	%
	Nondeductible guarantee fees		—				-0.9	%
	Impact of changes in rates		-0.2	%			-12.2	%
	Established/reversed tax deferrals (deferred tax liabilities) not thru provision		-68.8	%			-5.5	%
	Other		-1.3	%			—
	Valuation allowance for deferred income tax assets		13.2	%			-18	%
	Effective income tax rate		-0.1	%			-0.1	%

Equity_Tables

Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The Company had the following stock purchase warrants outstanding at December 31:
	Outstanding
	12/31/14	12/31/13				Exercise			Expiration		Classification
						Price
	-			200,000		$	1.5		14-Feb		Equity
	-			800,000		$	0.7		14-Jun		Equity
	-			1,180,547		$	1.42		14-Dec		Equity
	-			2,115,596		$	1.42		14-Dec		Equity
	1,070,916			1,070,916		$	0.51		15-Feb		Equity
	325,000			325,000		$	1.25		15-Feb		Equity
	325,000			325,000		$	1.5		15-Feb		Equity
	325,000			325,000		$	1.75		15-Feb		Equity
	1,295,138			1,295,138		$	0.54		15-Apr		Equity
	100,000			100,000		$	0.37		15-Oct		Equity
	1,488,839			1,488,839		$	0.6		16-Apr		Equity
	916,665			916,665		$	0.5		16-Apr		Equity
	20,000			-		$	0.4		16-Jun		Equity
	136,364			136,364		$	0.66		18-Feb		Equity
	6,363,638			6,363,638		$	0.75		18-Feb		Equity
	5,047,461			5,047,461		$	0.65		18-Dec		Equity*
	232,964			-		$	0.65		18-Dec		Equity
	2,884,615			-		$	0.52		19-Mar		Liability
	1,474,615			-		$	0.52		19-Mar		Liability
	3,525,000			-		$	0.52		19-Jun		Liability
	1,079,137			1,079,137		$	0.7		20-Feb		Equity
	250,000			250,000		$	0.7		20-Feb		Equity
	25,115,384			-		$	0.52		21-Mar		Liability
	67,500,000			-		$	0.52		21-Jun		Liability
	119,475,736			23,019,301
	* These warrants were reclassified to additional paid-in capital as a result of the expiration of non-standard anti-dilution clauses contained within the warrants.
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes information about stock options outstanding as of December 31, 2014:
			Options Outstanding							Options Exercisable
					Weighted		Weighted					Weighted
	Range of		Number of		Average		Average					Average
	Exercise		Outstanding		Remaining		Exercise			Number		Exercise
	Prices		Shares		Contract Life		Price			Exercisable		Price
	$0.30 - $0.50		3,049,748		8.11		$	0.41		954,164		$	0.43
	$0.51 - $0.75		7,721,900		8.4		$	0.6		2,932,999		$	0.6
	$0.76 - $1.25		805,000		5.4		$	0.95		805,000		$	0.95
	$1.26 - $1.75		1,733,477		3.91		$	1.42		1,732,477		$	1.42
	$1.76 - $2.75		825,500		2.42		$	2.32		803,665		$	2.32
	$2.76 - $4.50		0		0			—		0			—
	$4.51 - $6.00		70,000		1.03		$	5.2		70,000		$	5.2
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of service provider warrant activity as of December 31, 2014, and changes during 2014, is presented below:
								Weighted-
					Weighted-			Average
					Average			Remaining		Aggregate
					Exercise			Contractual		Intrinsic
	Warrants to Service Providers		Shares		Price			Term		Value
	Outstanding at January 1, 2014		1,661,364		$	1.24		1.9
	Granted		20,000		$	0.4
	Exercised		0			—
	Forfeited or expired		-200,000		$	1.5
	Outstanding at December 31, 2014		1,481,364		$	1.2		1.3		$	0
	Exercisable at  December 31, 2014		1,471,364		$	1.2		1.3		$	0
Schedule Of Warrants Outstanding [Table Text Block]	The following table summarizes information about these warrants outstanding as of December 31, 2014:
			Warrants Outstanding							Warrants Exercisable
					Weighted		Weighted					Weighted
	Range of		Number of		Average		Average					Average
	Exercise		Outstanding		Remaining		Exercise			Number		Exercise
	Prices		Shares		Contract Life		Price			Exercisable		Price
	$0.30 - $0.50		120,000		0.9		$	0.38		110,000		$	0.37
	$0.51 - $0.75		386,364		4.4		$	0.69		386,364		$	0.69
	$0.76 - $1.25		325,000		0.1		$	1.25		325,000		$	1.25
	$1.26 - $1.75		650,000		0.1		$	1.63		650,000		$	1.63
Schedule Of Share Based Compensation Expense [Table Text Block]	The Company has recorded stock-based compensation expense as follows:
			Year Ended December 31
	Stock-Based Expense		2014			2013
	Awards under the 2002 LTIP and 2013 EIP			1,269,150			679,550
	Awards outside the equity-based plans			10,145			38,313
			$	1,279,295		$	717,863
	Included in Statements of Operations caption as follows:
	Salaries and wages		$	1,154,767		$	564,737
	Consulting expense			10,145			16,278
	General and administrative			114,383			136,848
			$	1,279,295		$	717,863
Incentive Plan [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of stock option activity under the Plans as of December 31, 2014, and changes during 2014, is presented below:
								Weighted-
					Weighted-			Average
					Average			Remaining		Aggregate
					Exercise			Contractual		Intrinsic
	Stock Options		Shares		Price			Term		Value
	Outstanding at January 1, 2014		8,520,816		$	1.19
	Granted		8,462,248		$	0.55
	Exercised		0			—
	Forfeited or expired		-2,777,439		$	1.25
	Outstanding at December 31, 2014		14,205,625		$	0.8		7.2		$	2,000
	Exercisable at December 31, 2014		7,298,305		$	1.05		5.3		$	2,000

Supplemental_Cash_Flow_Disclos1

Supplemental Cash Flow Disclosures - Non-Cash Transactions (Tables)	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Non-cash Investing and Financing transactions for years ended December 31 include:
		2014		2013
	Conversion of convertible debt to common stock	$	3,067,423	$	523,927
	Reclassification of the unamortized balance of debt discount and derivative liability, related to the extinguishment and conversion of the subordinated convertible debt, to additional paid-in capital		2,860,627		—
	Derivative liability created from conversion option embedded in Deerfield convertible credit facility		8,825,935		—
	Effect of modification of convertible debt		—		151,032
	Common Stock issued for committed equity financing facility		—		204,015
	Warrants issued for term loan modification		—		151,758
	Warrants issued for term loan		—		568,324
	Common stock and warrants issued for release of security interest in patents		—		325,693
	Warrants issued in connection with convertible debt and equity facility		29,137,682		1,353,842
	Derivative liability for embedded conversion option		—		965,484
	Common stock issued for professional services		—		17,850
	Common stock issued for settlement of contingency		39,150		39,150
	Reclassification of warrant derivative liability to additional paid-in capital as a result of the expiration of non-standard anti-dilution clause contained in warrants		1,331,776		—
	Issuance of common stock in connection with convertible debt facility		1,050,000		—
	Common stock issued to satisfy contingent consideration		127		—
	Accrued property and equipment		64,108		—

Operating_Leases_Tables

Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2014
Leases, Operating [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	The Company leases its office spaces under operating leases with approximate future minimum lease payments as indicated in the table below:
	Years ending December 31:
	2015	$	439,000
	2016		451,000
	2017		463,000
	2018		441,000
	2019		122,000
	Thereafter		—
	Total future minimum lease payments	$	1,916,000

Geographic_Concentration_Infor1

Geographic Concentration Information (Tables)	12 Months Ended
	Dec. 31, 2014
Geographic Areas, Revenues from External Customers [Abstract]
Schedule Of Geographic Information On Revenues [Table Text Block]	Product sales consist of the following:
		Year Ended December 31,
		2014		2013
	Revenue from U.S. product sales	$	4,273,181	$	9,549,015
	Revenue from non-U.S. product sales		1,576,149		949,711
	Total revenue from product sales	$	5,849,330	$	10,498,726

Business_and_Presentation_Deta

Business and Presentation (Details) (USD $)	3 Months Ended		12 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Severance costs	$0	$320,000
Loss on abandonment of lease	243,000	0
Loss on disposal of assets	132,000	0	131,456	0
Total	$375,000	$320,000

Business_and_Presentation_Deta1

Business and Presentation (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free rate, Minimum	0.10%	0.40%
Risk free rate, Maximum	1.70%	1.40%
Weighted average expected years until exercise	6 years 3 months 18 days	5 years 10 months 24 days
Expected stock volatility, Minimum	118.00%	96.00%
Expected stock volatility, Maximum	127.00%	135.00%
Dividend yield	0.00%	0.00%

Business_and_Presentation_Deta2

Business and Presentation (Details Textual) (USD $)	1 Months Ended	12 Months Ended		1 Months Ended	3 Months Ended
	Jan. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Jun. 25, 2014	Mar. 31, 2014	Dec. 31, 2012
Concentration Risk, Percentage		5.00%
Allowance for Doubtful Accounts Receivable		$32,469	$16,497			$42,709
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		200,989,054	61,134,957
Repayments of Notes Payable		6,201,143	1,020,000
Debt Conversion, Converted Instrument, Amount		3,067,423	523,927
Cash		15,946,425	3,286,713			2,615,805
Deferred Licensing Revenue		1,442,000
Licenses Revenue		402,264	167,657
Medical Device Excise Tax Percentage	2.30%
Minimum Cash Balance		5,000,000
Restructuring Reserve		413,000
Product Warranty Accrual, Warranties Issued		600,000
Inventory Valuation Reserves		90,000	0
Minimum [Member]
Property, Plant and Equipment, Useful Life		3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life		5 years
Furniture Lab And Manufacturing Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life		7 years
Furniture Lab And Manufacturing Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life		10 years
Centrifuges [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life		3 years
Centrifuges [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life		6 years
Safe Harbor Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount		175,000	164,000
Convertible Debt Facility [Member]
Convertible Debt					35,000,000
Proceeds from Convertible Debt				26,000,000	9,000,000
Proceeds From Issuance Of Common Stock And Warrants					2,000,000
Repayments of Notes Payable					5,900,000
Repayments of Convertible Debt					300,000
Debt Conversion, Converted Instrument, Amount					3,100,000
Federal Deposit Insurance Corporation [Member]
Cash, Uninsured Amount		15,486,000	2,667,000
Arthrex [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage		64.00%
Arthrex [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage		91.00%	47.00%
Aldagen Inc [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net		422,000
Angel [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net		$707,000
Angel [Member] | Arthrex [Member]
Concentration Risk, Percentage		100.00%
Non United States [Member]
Percentage Of Product Sales		27.00%	9.00%

Arthrex_Distributor_and_Licens1

Arthrex Distributor and License Agreement (Details Textual) (Arthrex [Member], USD $)	Aug. 07, 2013
In Millions, unless otherwise specified
Arthrex [Member]
Arthrex Distributor And License Agreements [Line Items]
Retainage Deposit	$5

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in money market funds	$15,736,350	$2,303,556
Total investment in money market funds	15,736,350	2,303,556
Embedded conversion options	4,362,225	1,515,540
Stock purchase warrants	25,484,596	1,733,055
Total derivative liabilities	29,846,821	3,248,595
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in money market funds	15,736,350	2,303,556
Total investment in money market funds	15,736,350	2,303,556
Embedded conversion options	0	0
Stock purchase warrants	0	0
Total derivative liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in money market funds	0	0
Total investment in money market funds	0	0
Embedded conversion options	0	0
Stock purchase warrants	0	0
Total derivative liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment in money market funds	0	0
Total investment in money market funds	0	0
Embedded conversion options	4,362,225	1,515,540
Stock purchase warrants	25,484,596	1,733,055
Total derivative liabilities	$29,846,821	$3,248,595

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Stock purchase warrants [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Balance	$1,733,055		$0
Established in 2014	29,137,682		1,353,842
Modification of Convertible Debt Agreement	0		0
Effect of Conversion to Common Stock	0		0
Change in Fair Value	-4,054,365		379,213
Reclass to Equity	-1,331,776	[1]	0
Balance	25,484,596		1,733,055
Embedded conversion options [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Balance	1,515,540		780,960
Established in 2014	8,825,935		965,484
Modification of Convertible Debt Agreement	0		250,361
Effect of Conversion to Common Stock	-1,932,693		-393,948
Change in Fair Value	-4,046,557		90,839
Reclass to Equity	0	[1]	-178,156
Balance	$4,362,225		$1,515,540
[1]	Various warrants were reclassified to additional paid-in capital as a result of the expiration of non-standard anti-dilution clauses contained within the warrants.

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 2) (Fair Value, Measurements, Nonrecurring [Member], USD $)	Dec. 31, 2014
Intangible Assets Fair Value Disclosure	$26,632,229
Trademarks [Member]
Finite-lived Intangible Assets, Fair Value Disclosure	706,229
In-Process Research and Development Expense [Member]
Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure	25,926,000
Fair Value, Inputs, Level 1 [Member]
Intangible Assets Fair Value Disclosure	0
Fair Value, Inputs, Level 1 [Member] | Trademarks [Member]
Finite-lived Intangible Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 1 [Member] | In-Process Research and Development Expense [Member]
Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure	0
Fair Value, Inputs, Level 2 [Member]
Intangible Assets Fair Value Disclosure	0
Fair Value, Inputs, Level 2 [Member] | Trademarks [Member]
Finite-lived Intangible Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 2 [Member] | In-Process Research and Development Expense [Member]
Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure	0
Fair Value, Inputs, Level 3 [Member]
Intangible Assets Fair Value Disclosure	26,632,229
Fair Value, Inputs, Level 3 [Member] | Trademarks [Member]
Finite-lived Intangible Assets, Fair Value Disclosure	706,229
Fair Value, Inputs, Level 3 [Member] | In-Process Research and Development Expense [Member]
Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure	$25,926,000

Fair_Value_Measurements_Detail3

Fair Value Measurements (Details Textual) (USD $)	1 Months Ended	12 Months Ended
	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Time Deposits, at Carrying Value	$53,000
Time Deposits Annual Interest Rate	0.10%
Time Deposits Maturity Date	24-Jun-15
Impairment of Intangible Assets (Excluding Goodwill)		4,683,829	0
Trademarks [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)		1,025,000
In Process Research and Development [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Impairment of Intangible Assets (Excluding Goodwill)		$3,659,000

Receivables_Details

Receivables (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Trade receivables	$609,179	$2,449,199
Other receivables	1,312,617	1,493,979
Accounts Receivable, Gross, Current	1,921,796	3,943,178
Less allowance for doubtful accounts	-32,469	-16,497
Accounts and Other Receivables, Net, Current	$1,889,327	$3,926,681

Receivables_Details_1

Receivables (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]
Balance at Beginning of Period	$16,497	$42,709
Charged to Costs and Expenses	31,773	75,165
Balances charged-off	-15,801	-101,378
Balance at End of Period	$32,469	$16,497

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Raw materials	$121,631	$125,583
Finished goods	524,989	985,924
Inventory, Gross	646,620	1,111,507
Less provision for inventory obsolescence	-90,000	0
Inventory, Net	$556,620	$1,111,507

Prepaid_Expenses_and_Other_Cur2

Prepaid Expenses and Other Current Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Prepaid Expenses And Other Current Assets [Line Items]
Prepaid insurance	$125,106	$63,096
Prepaid fees and rent	249,046	151,454
Deposits and advances	1,360,672	279,870
Prepaid royalties	604,166	724,999
Other Current Assets	0	38,863
Prepaid Expense and Other Assets, Current	$2,338,990	$1,258,282

Prepaid_Expenses_and_Other_Cur3

Prepaid Expenses and Other Current Assets (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Prepaid Expenses And Other Current Assets [Line Items]
Amortization of Advance Royalty	$120,833	$100,694

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$1,599,699	$2,063,564
Less accumulated depreciation and amortization	-674,528	-1,144,095
Property, Plant and Equipment, Net	925,171	919,469
Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	801,463	1,278,681
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	150,411	86,001
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	307,851	307,971
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	32,130	390,911
Technology Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$307,844	$0

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Costs Of Depreciation And Amortization	$276,000	$726,000
Research Development Trials Studies Expenses	72,000	299,000
Costs Of Goods Sold Depreciation	105,000	310,000
Property, Plant and Equipment, Disposals	265,000	1,543,000
Centrifuges [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Disposals		$1,295,000

Goodwill_and_Identifiable_Inta2

Goodwill and Identifiable Intangible Assets (Details) (USD $)	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets, Net [Abstract]
Finite-Lived Intangible Assets, Gross	$30,036,000		$34,958,000
Less accumulated amortization	-1,288,230		-1,189,046
Intangible assets, net	28,747,770		33,768,954
Trademarks [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Finite-Lived Intangible Assets, Gross	1,047,000		2,310,000
Technology [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Finite-Lived Intangible Assets, Gross	2,355,000		2,355,000
Customer relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Finite-Lived Intangible Assets, Gross	708,000		708,000
In-process research and development [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$25,926,000	$29,600,000	$29,585,000

Goodwill_and_Identifiable_Inta3

Goodwill and Identifiable Intangible Assets (Details 1) (USD $)	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
2015	$308,400
2016	308,400
2017	308,400
2018	242,000
2019	219,900
Thereafter	$1,434,800

Goodwill_and_Identifiable_Inta4

Goodwill and Identifiable Intangible Assets (Details Textual) (USD $)	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets, Finite-lived	$1,000,000
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets, Finite-lived	3,700,000
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Trademarks, Gross	1,800,000	800,000
General and Administrative Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets		180,000
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	29,600,000	25,926,000	29,585,000
Royalty Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets		$157,000

Accrued_expenses_Details

Accrued expenses (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Customer deposits	$2,516,202	$1,795,803
Accrued compensation and benefits	984,227	795,584
Other payables	379,019	242,993
Accrued interest	1,025,623	2,250
Due to Arthrex	324,531	1,630,564
Accrued professional fees	285,446	199,634
Accrued loss on abandonment of lease, current portion	103,176	0
Accrued Angel machine refurbishment costs	600,000	0
Accrued Liabilities, Current	$6,218,224	$4,666,828

Accrued_expenses_Details_Textu

Accrued expenses (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued Angel Machine Refurbishment Costs	$600,000	$0

Deferred_Revenue_Details_Textu

Deferred Revenue (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Deferred Revenue Arrangement [Line Items]
Deferred Licensing Revenue Recognized Period	5 years
Licenses Revenue	$402,264	$167,657

Debt_Details_Textual

Debt (Details Textual) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

0 Months Ended

Dec. 10, 2013

Dec. 31, 2014

Jun. 09, 2014

Mar. 31, 2014

Jun. 30, 2014

Feb. 28, 2014

Nov. 21, 2013

Apr. 28, 2011

Apr. 28, 2014

Feb. 19, 2013

Dec. 31, 2013

Feb. 28, 2013

Apr. 30, 2011

Feb. 27, 2013

Jul. 15, 2011

Debt Conversion [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

6,363,638

Warrants Initial Value

1,100,000

Percentage In Number Of Shares

75.00%

Exercise Price On Market Price

125.00%

Common Stock [Member]

Debt Conversion [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

0.52

Second Draw [Member]

Debt Conversion [Line Items]

Stock Issued During Period, Shares, Other

2,709,677

Deerfield Facility Agreement [Member]

Debt Conversion [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.75%

Debt Instrument, Maturity Date

31-Mar-19

Equity Raising Transaction Proceeds Percentage Applied For Redemption

35.00%

Put Options Amount Exempt

10,000,000

Line of Credit Facility, Maximum Amount Outstanding During Period

35,000,000

Debt Instrument, Redemption Price, Percentage

33.33%

Deerfield Facility Agreement [Member] | First Draw [Member]

Debt Conversion [Line Items]

Debt Discount Convertible Debt

9,000,000

Warrants Fair Value

6,600,000

Warrants Initial Value

1,500,000

Line of Credit Facility, Maximum Amount Outstanding During Period

9,000,000

Embedded Derivative, Fair Value Of Embedded Derivative Liability

3,000,000

Deerfield Facility Agreement [Member] | Second Draw [Member]

Debt Conversion [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

97,614,999

Debt Discount Convertible Debt

25,800,000

Warrants Fair Value

21,500,000

Warrants Initial Value

2,600,000

Line of Credit Facility, Maximum Amount Outstanding During Period

26,000,000

Embedded Derivative, Fair Value Of Embedded Derivative Liability

5,300,000

Senior Secured Convertible Notes [Member]

Debt Conversion [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

0.00%

Debt Instrument, Convertible, Conversion Price

$0.52

Subordinated Convertible Notes [Member]

Debt Conversion [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Proceeds from Convertible Debt

2,250,000

750,000

3,000,000

Debt Discount Convertible Debt

2,250,000

Debt Conversion, Converted Instrument, Shares Issued

5,981,859

Deferred Debt Issuance Cost

69,000

Repayments of Convertible Debt

339,000

JP Nevada Trust 12% Note [Member]

Debt Conversion [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

750,000

1,000,000

266,666

533,334

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.52

$0.50

$0.70

$0.70

Derivative Liability

14,000

Debt Instrument, Fair Value Disclosure

2,100,000

Fair Value Of Warrants Issued

546,000

Related Party Guaranteed Obligations

1,400,000

JP Nevada Trust 12% Note [Member] | Second Draw [Member]

Debt Conversion [Line Items]

Deferred Debt Issuance Cost

298,000

JP Nevada Trust 12% Note [Member] | Promissory Note [Member]

Debt Conversion [Line Items]

Secured Debt

2,100,000

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Debt Instrument, Maturity Date

20-May-16

Class of Warrant or Right, Exercise Price of Warrants or Rights

0.5

JP Nevada Trust 12% Note [Member] | Guarantee [Member]

Debt Conversion [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,500,000

Midcap Financial Llc [Member]

Debt Conversion [Line Items]

Debt Discount Balance Expensed

381,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,079,137

Class of Warrant or Right, Exercise Price of Warrants or Rights

0.46

0.7

Term Loan Commitments

7,500,000

Term Loan Commitments Amount Modified

4,500,000

Term Loan First Tranche

4,500,000

Deferred Fee

142,000

Gains (Losses) on Extinguishment of Debt, before Write off of Deferred Debt Issuance Cost

330,000

Changes In Fair Value Warrants

12,000

Fair Value Of Warrants Issued

568,000

July Four Percent Convertible Notes [Member]

Debt Conversion [Line Items]

Secured Debt

$1,300,000

Debt Instrument, Convertible, Terms Of Conversion Feature

The July 4% Convertible Notes were scheduled to mature on May 23, 2016 and included a one-time interest charge of 4% due on maturity. The July 4% Convertible Notes (plus accrued interest) converted at the option of the holder, in whole or in part and from time to time, into shares of our common stock at a conversion rate equal to (i) the lesser of $0.80 per share or (ii) 80% of the average of the three lowest closing prices of our common stock for the previous 20 trading days prior to conversion (subject to a floor price of $0.25 per share).

Debt Instrument, Issuance Date

15-Jul-11

July Four Percent Convertible Notes [Member] | Common Stock [Member]

Debt Conversion [Line Items]

Debt Instrument, Convertible, Conversion Price

$0.41

Debt Conversion, Converted Instrument, Shares Issued

347,000

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Current:
Federal	$0	$0
State	0	0
Deferred:
Federal	9,513,282	-212,022
State	952,533	-401,215
Net operating loss carryforward	7,764,117	4,243,885
Valuation Allowance	-18,249,516	-3,649,237
Total income tax (expense) benefit	($19,584)	($18,589)

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:
Stock-based compensation	$5,942,000	$5,371,000
Tax credits	3,162,000	2,895,000
Deferred revenue	575,000	861,000
Start-up and organizational costs	276,000	272,000
Tax deductible Goodwill	88,000	112,000
Property and equipment	56,000	240,000
Other	389,000	153,000
Total deferred tax assets	10,488,000	9,904,000
Deferred tax liabilities:
Intangible Assets	-10,325,000	-12,219,000
Discount on Note Payable	-13,825,000	-1,088,000
Other	-89,000	-69,000
Total deferred tax liabilities	-24,239,000	-13,376,000
Net deferred tax assets, excluding net operating loss carryforwards	-13,751,000	-3,472,000
Net operating loss carryforwards	53,222,000	45,458,000
Deferred Tax Assets, Gross, Noncurrent	39,471,000	41,986,000
Less valuation allowance	-39,559,000	-42,055,000	-38,406,000
Total deferred tax assets (liabilities)	($88,000)	($69,000)

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax [Line Items]
Valuation allowance	$42,055,000	$38,406,000
Change in valuation	10,485,000	3,649,000
Valuation allowance	39,559,000	42,055,000
Establisment and reversal in 2014 - Convertible Bridge notes [Member]
Income Tax [Line Items]
Valuation allowance		897,000
Establishment in 2014 - Deerfield note [Member]
Income Tax [Line Items]
Valuation allowance		($13,878,000)

Income_Taxes_Details_3

Income Taxes (Details 3)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Line Items]
U.S. Federal statutory income tax	35.00%	35.00%
State and local income tax, net of benefits	4.90%	4.40%
Fair value of Derivatives	17.10%	-2.90%
Nondeductible guarantee fees	0.00%	-0.90%
Impact of changes in rates	-0.20%	-12.20%
Established/reversed tax deferrals (deferred tax liabilities) not thru provision	-68.80%	-5.50%
Other	-1.30%	0.00%
Valuation allowance for deferred income tax assets	13.20%	-18.00%
Effective income tax rate	-0.10%	-0.10%

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	$142,701,000
Deferred Tax Liability Provision For Income Tax	$20,000	$19,000

Equity_Details

Equity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Class of Warrant or Right, Outstanding	119,475,736		23,019,301
Stock Purchase Warrants [Member]
Class of Warrant or Right, Outstanding	0		200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.50		$1.50
Warrant Expiration Date	14-Feb		14-Feb
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants One [Member]
Class of Warrant or Right, Outstanding	0		800,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.70		$0.70
Warrant Expiration Date	14-Jun		14-Jun
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Two [Member]
Class of Warrant or Right, Outstanding	0		1,180,547
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.42		$1.42
Warrant Expiration Date	14-Dec		14-Dec
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Three [Member]
Class of Warrant or Right, Outstanding	0		2,115,596
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.42		$1.42
Warrant Expiration Date	14-Dec		14-Dec
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Four [Member]
Class of Warrant or Right, Outstanding	1,070,916		1,070,916
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.51		$0.51
Warrant Expiration Date	15-Feb		15-Feb
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Five [Member]
Class of Warrant or Right, Outstanding	325,000		325,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.25		$1.25
Warrant Expiration Date	15-Feb		15-Feb
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Six [Member]
Class of Warrant or Right, Outstanding	325,000		325,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.50		$1.50
Warrant Expiration Date	15-Feb		15-Feb
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Seven [Member]
Class of Warrant or Right, Outstanding	325,000		325,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.75		$1.75
Warrant Expiration Date	15-Feb		15-Feb
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Eight [Member]
Class of Warrant or Right, Outstanding	1,295,138		1,295,138
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.54		$0.54
Warrant Expiration Date	15-Apr		15-Apr
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Nine [Member]
Class of Warrant or Right, Outstanding	100,000		100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.37		$0.37
Warrant Expiration Date	15-Oct		15-Oct
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Ten [Member]
Class of Warrant or Right, Outstanding	1,488,839		1,488,839
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.60		$0.60
Warrant Expiration Date	16-Apr		16-Apr
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Eleven [Member]
Class of Warrant or Right, Outstanding	916,665		916,665
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.50		$0.50
Warrant Expiration Date	16-Apr		16-Apr
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Twelve [Member]
Class of Warrant or Right, Outstanding	20,000		0
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.40		$0.40
Warrant Expiration Date	16-Jun		16-Jun
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Thirteen [Member]
Class of Warrant or Right, Outstanding	136,364		136,364
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.66		$0.66
Warrant Expiration Date	18-Feb		18-Feb
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Fourteen [Member]
Class of Warrant or Right, Outstanding	6,363,638		6,363,638
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.75		$0.75
Warrant Expiration Date	18-Feb		18-Feb
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Fifteen [Member]
Class of Warrant or Right, Outstanding	5,047,461		5,047,461
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.65		$0.65
Warrant Expiration Date	18-Dec		18-Dec
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity*	[1]	Equity*	[1]
Stock Purchase Warrants Sixteen [Member]
Class of Warrant or Right, Outstanding	232,964		0
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.65		$0.65
Warrant Expiration Date	18-Dec		18-Dec
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Seventeen [Member]
Class of Warrant or Right, Outstanding	2,884,615		0
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.52		$0.52
Warrant Expiration Date	19-Mar		19-Mar
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Liability		Liability
Stock Purchase Warrants Eighteen [Member]
Class of Warrant or Right, Outstanding	1,474,615		0
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.52		$0.52
Warrant Expiration Date	19-Mar		19-Mar
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Liability		Liability
Stock Purchase Warrants Nineteen [Member]
Class of Warrant or Right, Outstanding	3,525,000		0
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.52		$0.52
Warrant Expiration Date	19-Jun		19-Jun
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Liability		Liability
Stock Purchase Warrants Twenty [Member]
Class of Warrant or Right, Outstanding	1,079,137		1,079,137
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.70		$0.70
Warrant Expiration Date	20-Feb		20-Feb
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Twenty One [Member]
Class of Warrant or Right, Outstanding	250,000		250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.70		$0.70
Warrant Expiration Date	20-Feb		20-Feb
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Equity		Equity
Stock Purchase Warrants Twenty Two [Member]
Class of Warrant or Right, Outstanding	25,115,384		0
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.52		$0.52
Warrant Expiration Date	21-Mar		21-Mar
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Liability		Liability
Stock Purchase Warrants Twenty Three [Member]
Class of Warrant or Right, Outstanding	67,500,000		0
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.52		$0.52
Warrant Expiration Date	21-Jun		21-Jun
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding	Liability		Liability
[1]	These warrants were reclassified to additional paid-in capital as a result of the expiration of non-standard anti-dilution clauses contained within the warrants.

Equity_Details_1

Equity (Details 1) (Long Term Incentive Plan [Member], Equity Incentive Plan [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Long Term Incentive Plan [Member] | Equity Incentive Plan [Member]
Outstanding at January 1, 2014	8,520,816
Granted - Shares	8,462,248
Exercised - Shares	0
Forfeited or expired - Shares	-2,777,439
Outstanding at December 31, 2014	14,205,625
Exercisable at December 31, 2014	7,298,305
Outstanding Opening Balance - Weighted-Average Exercise Price	$1.19
Granted - Weighted - Average Exercise Price	$0.55
Exercised - Weighted-Average Exercise Price	$0
Forfeited or Expired - Weighted - Average Exercise Price	$1.25
Outstanding Ending Balance - Weighted-Average Exercise Price	$0.80
Options Exercisable - Weighted - Average Exercise Price	$1.05
Options Outstanding - Weighted Average Remaining Contract Life	7 years 2 months 12 days
Exercisable - Weighted-Average Remaining Contractual Term	5 years 3 months 18 days
Outstanding - Aggregate Intrinsic Value	$2,000
Exercisable - Aggregate Intrinsic Value	$2,000

Equity_Details_2

Equity (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014
Exercise Price Range One [Member]
Exercise Price Upper Range Limit	$0.50
Exercise Price Lower Range Limit	$0.30
Options Outstanding - Shares	3,049,748
Options Outstanding - Weighted Average Remaining Contract Life	8 years 1 month 10 days
Options Outstanding - Weighted - Average Exercise Price	$0.41
Options Exercisable - Shares	954,164
Options Exercisable - Weighted - Average Exercise Price	$0.43
Exercise Price Range Two [Member]
Exercise Price Upper Range Limit	$0.75
Exercise Price Lower Range Limit	$0.51
Options Outstanding - Shares	7,721,900
Options Outstanding - Weighted Average Remaining Contract Life	8 years 4 months 24 days
Options Outstanding - Weighted - Average Exercise Price	$0.60
Options Exercisable - Shares	2,932,999
Options Exercisable - Weighted - Average Exercise Price	$0.60
Exercise Price Range Three [Member]
Exercise Price Upper Range Limit	$1.25
Exercise Price Lower Range Limit	$0.76
Options Outstanding - Shares	805,000
Options Outstanding - Weighted Average Remaining Contract Life	5 years 4 months 24 days
Options Outstanding - Weighted - Average Exercise Price	$0.95
Options Exercisable - Shares	805,000
Options Exercisable - Weighted - Average Exercise Price	$0.95
Exercise Price Range Four [Member]
Exercise Price Upper Range Limit	$1.75
Exercise Price Lower Range Limit	$1.26
Options Outstanding - Shares	1,733,477
Options Outstanding - Weighted Average Remaining Contract Life	3 years 10 months 28 days
Options Outstanding - Weighted - Average Exercise Price	$1.42
Options Exercisable - Shares	1,732,477
Options Exercisable - Weighted - Average Exercise Price	$1.42
Exercise Price Range Five [Member]
Exercise Price Upper Range Limit	$2.75
Exercise Price Lower Range Limit	$1.76
Options Outstanding - Shares	825,500
Options Outstanding - Weighted Average Remaining Contract Life	2 years 5 months 1 day
Options Outstanding - Weighted - Average Exercise Price	$2.32
Options Exercisable - Shares	803,665
Options Exercisable - Weighted - Average Exercise Price	$2.32
Exercise Price Range Six [Member]
Exercise Price Upper Range Limit	$4.50
Exercise Price Lower Range Limit	$2.76
Options Outstanding - Shares	0
Options Outstanding - Weighted Average Remaining Contract Life	0 years
Options Exercisable - Shares	0
Exercise Price Range Seven [Member]
Exercise Price Upper Range Limit	$6
Exercise Price Lower Range Limit	$4.51
Options Outstanding - Shares	70,000
Options Outstanding - Weighted Average Remaining Contract Life	1 year 11 days
Options Outstanding - Weighted - Average Exercise Price	$5.20
Options Exercisable - Shares	70,000
Options Exercisable - Weighted - Average Exercise Price	$5.20

Equity_Details_3

Equity (Details 3) (Warrant [Member], Performance Shares [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member] | Performance Shares [Member]
Outstanding at January 1, 2014 - Shares	1,661,364
Granted - Shares	20,000
Exercised - Shares	0
Forfeited or expired - Shares	-200,000
Outstanding at December 31, 2014 -Shares	1,481,364	1,661,364
Exercisable at December 31, 2014 - Shares	1,471,364
Weighted-Average Exercise Price, Outstanding, Beginning	$1.24
Granted - Weighted - Average Exercise Price	$0.40
Exercised - Weighted - Average Exercise Price	$0
Forfeited or expired - Weighted - Average Exercise Price	$1.50
Weighted-Average Exercise Price, Outstanding, Ending	$1.20	$1.24
Exercisable - Weighted - Average Exercise Price	$1.20
Outstanding - Weighted-Average Remaining Contractual Term	1 year 3 months 18 days	1 year 10 months 24 days
Exercisable - Weighted-Average Remaining Contractual Term	1 year 3 months 18 days
Outstanding - Aggregate Intrinsic Value	$0
Exercisable - Aggregate Intrinsic Value	$0

Equity_Details_4

Equity (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2014
Exercise Price Range One [Member]
Number of Outstanding Shares, Warrants Outstanding	120,000
Weighted Average Remaining Contract Life, Warrants Outstanding	10 months 24 days
Weighted Average Exercise Price, Warrants Outstanding	$0.38
Number Exercisable, Warrants Exercisable	110,000
Weighted Average Exercise Price, Warrants Exercisable	$0.37
Exercise Price Range One [Member] | Maximum [Member]
Range of Exercise Prices	$0.50
Exercise Price Range One [Member] | Minimum [Member]
Range of Exercise Prices	$0.30
Exercise Price Range Two [Member]
Number of Outstanding Shares, Warrants Outstanding	386,364
Weighted Average Remaining Contract Life, Warrants Outstanding	4 years 4 months 24 days
Weighted Average Exercise Price, Warrants Outstanding	$0.69
Number Exercisable, Warrants Exercisable	386,364
Weighted Average Exercise Price, Warrants Exercisable	$0.69
Exercise Price Range Two [Member] | Maximum [Member]
Range of Exercise Prices	$0.75
Exercise Price Range Two [Member] | Minimum [Member]
Range of Exercise Prices	$0.51
Exercise Price Range Three [Member]
Number of Outstanding Shares, Warrants Outstanding	325,000
Weighted Average Remaining Contract Life, Warrants Outstanding	1 month 6 days
Weighted Average Exercise Price, Warrants Outstanding	$1.25
Number Exercisable, Warrants Exercisable	325,000
Weighted Average Exercise Price, Warrants Exercisable	$1.25
Exercise Price Range Three [Member] | Maximum [Member]
Range of Exercise Prices	$1.25
Exercise Price Range Three [Member] | Minimum [Member]
Range of Exercise Prices	$0.76
Exercise Price Range Four [Member]
Number of Outstanding Shares, Warrants Outstanding	650,000
Weighted Average Remaining Contract Life, Warrants Outstanding	1 month 6 days
Weighted Average Exercise Price, Warrants Outstanding	$1.63
Number Exercisable, Warrants Exercisable	650,000
Weighted Average Exercise Price, Warrants Exercisable	$1.63
Exercise Price Range Four [Member] | Maximum [Member]
Range of Exercise Prices	$1.75
Exercise Price Range Four [Member] | Minimum [Member]
Range of Exercise Prices	$1.26

Equity_Details_5

Equity (Details 5) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation	$1,279,295	$717,863
Awards under the 2013 EIP [Member]
Share-based Compensation	1,269,150	679,550
Awards outside the equity-based plans [Member]
Share-based Compensation	10,145	38,313
Salaries and wages [Member]
Share-based Compensation	1,154,767	564,737
Consulting expense [Member]
Share-based Compensation	10,145	16,278
General and administrative [Member]
Share-based Compensation	$114,383	$136,848

Equity_Details_Textual

Equity (Details Textual) (USD $)	0 Months Ended	12 Months Ended		1 Months Ended		3 Months Ended	1 Months Ended		23 Months Ended	1 Months Ended
	Feb. 19, 2013	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2014	Mar. 31, 2014	Mar. 31, 2014	Apr. 30, 2011	Feb. 28, 2013	Dec. 31, 2014	Nov. 30, 2014	Jun. 09, 2014	Jun. 08, 2014	Apr. 28, 2011
Schedule of Equity Method Investments [Line Items]
Class Of Warrant Or Right Outstanding		119,475,736	23,019,301						119,475,736
Proceeds from Issuance of Private Placement	$5,000,000
Share Price	$0.55
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	6,363,638
Stock Issued During Period, Shares, New Issues	9,090,911
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 10 months 24 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options		1,000							1,000
Investment Warrants, Exercise Price	$0.75
Common Stock, Par or Stated Value Per Share		$0.00	$0.00						$0.00
Common Stock, Shares Authorized		425,000,000	200,000,000						425,000,000		425,000,000	200,000,000
Authorized Shares, Common And Preferred											440,000,000	215,000,000
Warrants Initial Value		1,100,000							1,100,000
Proceeds From Issuance Of Common Stock		3,666,260	5,462,132
Stock Granted, Value, Share-based Compensation, Gross		1,037,000	712,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		2,400,000							2,400,000
Deerfield Facility Agreement [Member]
Schedule of Equity Method Investments [Line Items]
Stock Issued During Period, Shares, New Issues				1,100,000
Stock Issued During Period, Value, New Issues				2,709,677
Long Term and Equity Incentive Plan [Member]
Schedule of Equity Method Investments [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$0.40	$0.45
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		8,462,248	1,038,000
March 2014 Equity Offering [Member]
Schedule of Equity Method Investments [Line Items]
Proceeds from Issuance of Private Placement					2,000,000
Share Price					$0.52	$0.52
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					2,884,615	2,884,615
Stock Issued During Period, Shares, New Issues						3,846,154
Payments of Stock Issuance Costs						136,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$0.52	$0.52
Warrants Initial Value					1,100,000	1,100,000
Criteria One [Member]
Schedule of Equity Method Investments [Line Items]
Warrants Exercisable If Note is Outstanding On Noted Anniversary							57,143
Criteria Two [Member]
Schedule of Equity Method Investments [Line Items]
Warrants Exercisable If Note is Outstanding On Noted Anniversary							57,143
Long Term Incentive Plan [Member]
Schedule of Equity Method Investments [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		2,416,721							2,416,721		10,500,000
Equity Incentive Plan [Member]
Schedule of Equity Method Investments [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		11,345,852							11,345,852		18,000,000
Lincoln Park [Member]
Schedule of Equity Method Investments [Line Items]
Common Stock Capital Shares Reserved For Future Issuance Value								15,000,000
Shares Issuable Under Purchase Agreements								150,000
Increase In Shares Issuable Under Purchase Agreements								200,000
Minimum Closing Sale Price Per Share								$1
Shares Issued In Private Placement Maximum Percentage								9.99%
Stock Issued During Period, Shares, New Issues									5,250,000
Condition For Accelerated Purchase By Accredited Investor Minimum Share Price								$0.45
Additional Shares Issued Or To Be Issued		375,000
Additional Shares To Be Issued Related To Transaction Fee		375,000
Additional Shares Issued Related To Transaction Fee		59,126
Proceeds From Issuance Of Common Stock									2,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date		17-Jan-15
Number Of Shares Available To Issue									4,750,000
Value Of Shares Available To Issue									12,600,000
JMJ Note [Member]
Schedule of Equity Method Investments [Line Items]
Note Converted Into Common Shares								100,000
Debt Instrument Remitted Payment								370,000
Jp Nevada Trust Note [Member]
Schedule of Equity Method Investments [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					750,000	750,000	533,334	266,666					1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$0.52	$0.52	0.7	$0.70					$0.50
Warrants Exercisable							500,000	250,000
Guarantor Obligations, Current Carrying Value							1,400,000
Jp Nevada Trust Note [Member] | Criteria One [Member]
Schedule of Equity Method Investments [Line Items]
Warrants Exercisable If Note is Outstanding On Noted Anniversary							266,667	133,333
Jp Nevada Trust Note [Member] | Criteria Two [Member]
Schedule of Equity Method Investments [Line Items]
Warrants Exercisable If Note is Outstanding On Noted Anniversary							107,143	133,333
Aldagen [Member]
Schedule of Equity Method Investments [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares										1,270,000
February 2013 Worden Warrants [Member]
Schedule of Equity Method Investments [Line Items]
Class Of Warrant Or Right Outstanding								250,000
Royalty Expense								500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$0.70
February 2013 Warrants [Member]
Schedule of Equity Method Investments [Line Items]
Placement Fee			402,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			136,364
Warrant Exercise Price Percentage			120.00%
February 2013 Warrants [Member] | Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Future Annual Royalty Limitation								600,000
February 2013 Warrants [Member] | Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Future Annual Royalty Limitation								$625,000
Warrant [Member]
Schedule of Equity Method Investments [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		6 months
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted			486,364
Common Stock [Member]
Schedule of Equity Method Investments [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.52							$0.52

Supplemental_Cash_Flow_Disclos2

Supplemental Cash Flow Disclosures - Non-Cash Transactions (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Condensed Cash Flow Statements, Captions [Line Items]
Conversion of convertible debt to common stock	$3,067,423	$523,927
Reclassification of the unamortized balance of debt discount and derivative liability, related to the extinguishment and conversion of the subordinated convertible debt, to additional paid-in capital	2,860,627	0
Derivative liability created from conversion option embedded in Deerfield convertible credit facility	8,825,935	0
Effect of modification of convertible debt	0	151,032
Common Stock issued for committed equity financing facility	0	204,015
Warrants issued for term loan modification	0	151,758
Warrants issued for term loan	0	568,324
Common stock and warrants issued for release of security interest in patents	0	325,693
Warrants issued in connection with convertible debt and equity facility	29,137,682	1,353,842
Derivative liability for embedded conversion option	0	965,484
Common stock issued for professional services	0	17,850
Common stock issued for settlement of contingency	39,150	39,150
Reclassification of warrant derivative liability to additional paid-in capital as a result of the expiration of non-standard anti-dilution clause contained in warrants	1,331,776	0
Issuance of common stock in connection with convertible debt facility	1,050,000	0
Common stock issued to satisfy contingent consideration	127	0
Accrued property and equipment	$64,108	$0

Supplemental_Cash_Flow_Disclos3

Supplemental Cash Flow Disclosures - Non-Cash Transactions (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Condensed Cash Flow Statements, Captions [Line Items]
Interest Paid	$379,000	$564,000
Income Taxes Paid	$0	$0

Operating_Leases_Details

Operating Leases (Details) (USD $)	Dec. 31, 2014
Operating Leases [Line Items]
2015	$439,000
2016	451,000
2017	463,000
2018	441,000
2019	122,000
Thereafter	0
Total future minimum lease payments	$1,916,000

Operating_Leases_Details_Textu

Operating Leases (Details Textual) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Aug. 01, 2014
Operating Leases [Line Items]
Operating Leases, Rent Expense, Net	$515,000	$324,000
Operating Leases, Future Minimum Payments Due	1,916,000
Gaithersburg, Maryland [Member]
Operating Leases [Line Items]
Area Of Operating Lease Property	12,000
Gaithersburg, Maryland [Member] | Lease One [Member] | September 2019 [Member]
Operating Leases [Line Items]
Operating Leases, Future Minimum Payments Due	13,000
Gaithersburg, Maryland [Member] | Lease Two [Member] | September 2019 [Member]
Operating Leases [Line Items]
Operating Leases, Future Minimum Payments Due	4,000
Durham, North Carolina [Member]
Operating Leases [Line Items]
Area Of Operating Lease Property	16,300
Operating Leases, Rent Expense, Net	242,000
Future Sublease Rental Income			13,000
Durham, North Carolina [Member] | December 31, 2018 [Member]
Operating Leases [Line Items]
Operating Leases, Future Minimum Payments Due	20,000
Nashville, Tennessee [Member]
Operating Leases [Line Items]
Area Of Operating Lease Property	2,076
Nashville, Tennessee [Member] | April 30, 2018 [Member]
Operating Leases [Line Items]
Operating Leases, Future Minimum Payments Due	$4,000

Geographic_Concentration_Infor2

Geographic Concentration Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Geographic Areas, Revenues from External Customers [Line Items]
Product sales	$5,849,330	$10,498,726
U.S. product sales [Member]
Geographic Areas, Revenues from External Customers [Line Items]
Product sales	4,273,181	9,549,015
Non-U.S. product sales [Member]
Geographic Areas, Revenues from External Customers [Line Items]
Product sales	$1,576,149	$949,711

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended	12 Months Ended		1 Months Ended	3 Months Ended
	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2009	Sep. 30, 2008
Commitments and Contingencies [Line Items]
Research And Development		$368,000
Common Stock, Shares to be Issued		325,000
Time Deposits Maturity Date	24-Jun-15
Common Stock Shares Issuable		271,000
Series A Preferred Stock Contingency [Member]
Commitments and Contingencies [Line Items]
Revenues, Total		10,000,000
Aldagen Contingent Consideration [Member]
Commitments and Contingencies [Line Items]
Business Acquisitions Contingent Consideration Shares Issuable		20,309,723
Operating Expense Recognized Value			1,006,000
Business Acquisition Contingent Consideration Shares Issued		1,270,000
Deerfield Registration Rights Agreement [Member] | March Warrant [Member]
Commitments and Contingencies [Line Items]
Warrants to Purchase of Common Stock		25,115,384
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.52
Deerfield Registration Rights Agreement [Member] | June Warrant [Member]
Commitments and Contingencies [Line Items]
Warrants to Purchase of Common Stock		67,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.52
Maryland [Member]
Commitments and Contingencies [Line Items]
Deposit Interest Rate				0.10%
Time Deposits Maturity Date				24-Jun-15
Maryland [Member] | Letter of Credit [Member]
Commitments and Contingencies [Line Items]
Debt Instrument, Face Amount				50,000
Minimum [Member]
Commitments and Contingencies [Line Items]
Estimated Research Development Cost					500,000
Maximum [Member]
Commitments and Contingencies [Line Items]
Estimated Research Development Cost					$700,000
Maximum [Member] | Deerfield Warrants [Member]
Commitments and Contingencies [Line Items]
Shares Issuable Limit		92,615,385
Maximum [Member] | Deerfield facility [Member]
Commitments and Contingencies [Line Items]
Shares Issuable Limit		67,307,692

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], Millennia Holdings, Inc [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Subsequent Event [Member] | Millennia Holdings, Inc [Member]
Subsequent Event [Line Items]
Licensing and Distribution Agreement Amendment Description	We executed Amendment No. 5 to the Licensing and Distribution Agreement with Millennia dated September 10, 2009, as subsequently amended to terminate the Millennia Agreement and to allow us to transfer the exclusivity rights from Millennia to Rohto. In connection with this amendment we paid a one-time, non-refundable fee of $1.5 million to Millennia upon our receipt of the $3.0 million upfront payment from Rohto and may be required to pay certain future royalty payments to Millennia based upon net sales in Japan.
License Agreement Upfront Fee	$3
License Agreement Termination Fee	$1.50